Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
05/2009 | Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions May archived by USPTO category 05/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
05/28/2009 > patent applications in patent subcategories. archived by USPTO category

20090137452 - Antagonists of the bradykinin b1 receptor: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.... Agent: Amgen Inc.

20090137453 - Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof: The invention concerns a composition containing at least an oxazolin, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an alkanolamide, an oxazolidinone and a carbamic acid derivative. The invention also concerns... Agent: Birch Stewart Kolasch & Birch

20090137451 - Methods for assessing suitability of cancer patients for treatment with histone deacetylase inhibitors: This invention is in the field of cancer therapy and provides the use of E2F1 activity for assessing suitability of a cancer patient for treatment with histone deacetylase inhibitors (HDACIs).... Agent: Clark & Elbing LLP

20090137454 - Insulin derivatives: The present invention is related to insulin derivatives having a side chain attached to an ε-amino group of a Lys residue present in the A-chain or to an ε-amino group of a Lys residue in the B-chain.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090137455 - Rapid acting and long acting insulin combination formulations: An injectable formulation containing a combination of a rapid acting insulin and a long acting insulin has been developed wherein the pH of the rapid acting insulin is adjusted so that the long acting insulin, e.g. insulin glargine, remains soluble when they are mixed together. In the preferred embodiment, this... Agent: Pabst Patent Group LLP

20090137456 - Glucagon analogs exhibiting physiological solubility and stability: Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both.... Agent: Barnes & Thornburg LLP

20090137457 - Pyrimidinedione derivatives: This invention relates to novel compounds that are pyrimidinedione derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrimidinedione derivatives that are derivatives of alogliptin. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the use of the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090137458 - Methods and compositions for increasing skin remodeling: Skin remodeling is stimulated at the site of blemished skin using an ionic metal-peptide complex to diminish or remove the skin imperfection. The blemish can be a scar, especially surgical or wound scars, acne scars, keloid scars, and the like, or a skin tag, callus, benign skin mole, stretch marks,... Agent: Townsend And Townsend And Crew, LLP

20090137461 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137460 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20090137459 - Food product for enteral or oral nutrition: This invention relates to a food product for enteral or oral nutrition, comprising a novel protein mixture, a novel lipid mixture, as well as carbohydrates, soluble and insoluble fibre, vitamins and minerals, composing a nutritional product adequate for pathologic conditions where there is some kind of impairment to meet nutritional... Agent: Quinn Emanuel Urquhart Oliver & Hedges Koda/androlia

20090137462 - Pharmaceutical composition comprising cyclic somatostatin analogues: The present invention describes parenteral pharmaceutical compositions comprising a somatostatin analogue and novel somatostatin analogues.... Agent: Novartis Corporate Intellectual Property

20090137476 - Apo-2 ligand variants and uses thereof: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.... Agent: Genentech, Inc.

20090137467 - Bipartite inhibitors of bacterial rna polymerase: The invention provides a compound having a structural formula (I): X-α-Y, wherein X is an moiety that binds to the Rif pocket of a bacterial RNA polymerase, Y is a moiety that binds to the secondary channel of a bacterial RNA polymerase, and α is a linker. The compound can... Agent: Daniel A Scola & James F Harrington

20090137472 - Chimeric mhc protein and oligomer thereof: The invention concerns a oligomeric MHC complex comprising at least two chimeric proteins, said chimeric proteins comprising a first section derived from an MHC peptide chain or a functional part thereof and a second section comprising an oligomerising domain derived from an oligomer-forming coiled-coil protein, wherein formation of the oligomeric... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090137468 - Cytotoxic factors for modulating cell death: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death. The present inventors have found that different pathogens produce different cytotoxic... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090137478 - Hormone normalization therapy and uses therefor: The present invention discloses a novel method of prevention of birth defects, miscarriages and infertility in women. The two therapies, disclosed herein, the hormone normalization therapy and the aromatase inhibitor-hormone normalization therapy, focus on restoring young hormonal levels in women in order to prevent female infertility and miscarriages, guide follicular... Agent: Benjamin Aaron Adler Adler & Associates

20090137473 - Inhibition of microtubule protrusion in cancer cells: The present invention generally concerns microtubule protrusions in cancer cells, including detached cancer cells, and inhibition of the protrusions. In particular aspects, the inhibition of the protrusions interferes with attachment of the cell to a vessel wall, and in further aspects the cell is killed by forcing it to enter... Agent: Fulbright & Jaworski, LLP

20090137475 - Medicaments and proteins based on tgf-beta monomers for the treatment of wounds: There is provided the use of monomeric TGF-βs, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-β3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in... Agent: Goodwin Procter LLP Patent Administrator

20090137479 - Methods of treating and diagnosing laminopathy: The invention provides a method of treating laminopathy in a subject comprising administering a therapeutically effective amount of centrobin polypeptide to the subject such that laminopathy is treated. The invention also provides a method of identifying an agent that enhances nuclear envelope integrity. The method comprises administering an agent to... Agent: Marshall, Gerstein & Borun LLP

20090137470 - Methods of treating cancer using notch pathway inhibitors: The present invention is based on the discovery that the Notch signaling pathway is associated with cancer. Accordingly, the invention provides methods and compositions for treating cancer. Also provided are methods of modulating the expression and/or activity of proteins in the Notch signaling pathway for use in diagnoses and treatment... Agent: Dla Piper LLP (us)

20090137471 - Ngf variants: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are... Agent: Goodwin Procter LLP

20090137465 - Novel use: The present invention relates generally to the use of PA131 polypeptides and polynucleotides for healing various wounds arising from different causes.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090137464 - Therapeutic fibrin-derived peptides and uses thereof: The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R1 and R2 are either the same or different, wherein R1 and R2 are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from... Agent: Baker Botts L.L.P.

20090137480 - Transdermal delivery system for dried particulate or lyophilized medications: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal... Agent: Winston & Strawn LLP Patent Department

20090137463 - Treatment for neurodegeneration: Polypeptides which are an N- and/or C-terminally truncated fragment of the human osteopontin (hOPN) sequence or species variant, and which minimally have a 15 amino acid sequence corresponding to amino acids 138 to 152 of hOPN, and polynucleotides encoding said polypeptide, are useful for treatment or prevention of neurodegeneration.... Agent: Banner & Witcoff, Ltd.

20090137477 - Treatment of oropharyngeal candidiasis in cancer patients: A method for local treatment of severe oral lesions caused by oropharyngeal candidiasis in immunocompromised patients, in particularly having head and neck cancer and undergoing or have undergone radiation therapy, by administering a prolonged release mucoadhesive tablet containing at least one active principle of miconazole. Methods of treating xerostomia in... Agent: Birch Stewart Kolasch & Birch

20090137469 - Use of adnf polypeptides for treating peripheral neurotoxicity: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly... Agent: Townsend And Townsend And Crew, LLP

20090137466 - Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling: The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090137474 - Use of polypeptides having antimicrobial activity: The present invention relates to the use of polypeptides related to a Bacillus licheniformis polypeptide (amino acids 1-85 of SEQ ID NO: 2) as antimicrobial agents, for example in pharmaceutical applications, including veterinary applications, as well as for preservation, cleaning and disinfection of various surfaces, objects and substances. The polypeptides... Agent: Novozymes North America, Inc.

20090137481 - Antimicrobial polypeptides: The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20090137483 - Antagonists of the bradykinin b1 receptor: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.... Agent: Amgen Inc.

20090137482 - Biologically active peptide and agent containing the same: A peptide having any one of the amino acid sequences of SEQ ID NO: 1 or 13, preferably a peptide having any one of the amino acid sequences of SEQ ID NOS: 2 to 9 or a peptide having any one of the amino acid sequences of SEQ ID NOS:... Agent: Knobbe Martens Olson & Bear LLP

20090137486 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137487 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137488 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137489 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137490 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137491 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137485 - Antigens targeted by pathogenic t cells in type 1 diabetes and uses thereof: Provided are polypeptides that are capable of binding a human HLA-A2 MHC class I molecule. Kits comprising these polypeptides in a container are also provided. Further provided are methods for determining whether a mammal is at risk for or has type 1 diabetes. Additionally provided are methods of preventing a... Agent: Amster, Rothstein & Ebenstein LLP

20090137492 - Method to reduce the risk and/or severity of anthrax infection: Neuropeptides are used to treat mammals who have been exposed to or who are suspected of having been exposed to spores of Bacillus anthracis. The treatment provides a dose-dependent protection from the lethal consequences of infections.... Agent: Jones Day

20090137484 - Neuronal network-interacting peptide: The invention provides a method for treating a neuronal-associated condition comprising administering a composition comprising a therapeutically effective amount of a polypeptide or a biologically active fragment thereof, the polypeptide or the fragment thereof capable of modulating the interaction between Nogo-ephrinB and/or Nogo-Grb4 third SH3 domain. There are also provided... Agent: Donald R Studebaker Nixon Peabody

20090137493 - Inhibition of tumor metastases using protein kinase c (pkc) inhibitors: Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme.... Agent: King & Spalding LLP

20090137494 - Tumor-activated prodrug compounds and treatment: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20090137495 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090137497 - Active ingredient combinations of glucosyl glycerides and creatine and/or creatinine: Active ingredient combinations of one or more glucosyl glycerides and one or more substances selected from creatine, creatinine, creatine phosphate, creatine sulfate, creatine acetate, creatine ascorbate, and creatine derivatives whose carboxyl group is esterified by a mono- or polyfunctional alcohol, and cosmetic preparations comprising these active ingredient combinations.... Agent: Greenblum & Bernstein, P.L.C

20090137498 - Substituted benzene derivatives or salts thereof: There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients are the compounds such as 4′-bromo-2′-[(5-chloro-2-pyridyl)carbamoyl]-6′-β-D-galactopyranosyloxy-1-isopropylpiperidine-4-carboxanilide, 2′-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-4′-bromo-6′-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide, etc. or salts thereof.... Agent: Fitzpatrick Cella Harper & Scinto

20090137496 - Use of active ingredients containing hydroxystilbene for preventing and/or treating osteoporosis: The invention relates to the use of a combination of active ingredients containing hydroxystilbene, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the... Agent: Edwards Angell Palmer & Dodge LLP

20090137499 - Benzylphenyl glucopyranoside derivative: R1 represents a hydrogen atom, an amino group, a hydroxy C1-C6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, etc.; R4 represents a hydrogen atom, a C2-C7 acyl group, etc.; R5, R6, R7, and R8 are the same... Agent: Morgan & Finnegan Transition Team C/o Locke Lord Bissell & Liddell

20090137515 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137516 - Compositions and methods of treating dyslipidemia: The invention relates to the treatment of subjects for the purpose of reducing serum LDL, VLDL, triglycerides and fatty acids, by administering agents which reduce the activity of the bile acid pathway component SHP. Methods and pharmaceutical preparations comprising such agents are provided.... Agent: Wyeth Patent Law Group

20090137505 - Method for predicting and identifying target mrnas controlled by functional rnas and method of using the same: A method of predicting or identifying miRNAs and one or more target mRNAs targeted thereby, which comprises calculating the most stable secondary structures of double-stranded RNAs, which can be formed by all partial sequences in all of the subject mRNAs with miRNAs, and the secondary structure energies thereof to thereby... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090137514 - Methods and compositions for silencing genes without inducing toxicity: The present invention provides methods of post-transcriptional gene silencing which involve the use of a first dsRNA having substantial sequence identity to a target nucleic acid and a short, second dsRNA which inhibits dsRNA-mediated toxicity. These methods can be used to prevent or treat a disease or infection by silencing... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090137504 - Microrna target site blocking oligos and uses thereof: The present invention related to nucleic acids designed to prevent the binding of endogenous or exogenous microRNA and diagnostic and therapeutic uses thereof.... Agent: Clark & Elbing LLP

20090137503 - Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer: Acyclic nucleoside analogs such as acyclovir, ganciclovir, penciclovir and the corresponding pro-drugs, i.e., valacyclovir, valganciclovir and famciclovir, respectively have been identified as inhibitors or antagonists of both telomerase (encoded by TERT) and reverse transcriptase encoded by L-1 (LINE-1) RT, and as useful for treating or preventing cancers induced or mediated... Agent: Reed Smith LLP

20090137501 - Resistance genes: Genes involved in immune resistance to infection and uses thereof are described. In particular genes which are involved in resistance to HIV infection and in slowing disease progression in infected individuals are described.... Agent: Bozicevic, Field & Francis LLP

20090137502 - Riproximin, a novel type ii ribosome-inactivating protein and uses thereof: Described is a novel type II ribosome-inactivating protein, riproximin, as well as nucleic acid molecules encoding said protein. Furthermore, therapeutic uses of riproximin are described.... Agent: Baker & Daniels LLP

20090137513 - Rna interference mediated inhibition of acetyl-coa-carboxylase gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating acetyl-CoA carboxylase gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of acetyl-CoA carboxylase gene expression and/or... Agent: Sirna Therapeutics, Inc.

20090137507 - Rna interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating Angiopoietin gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Angiopoietin gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090137506 - Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina): The invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3. The invention relates to double stranded nucleic acid molecules including... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20090137512 - Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating cyclin (e.g., cyclin D1) and/or cyclin dependent kinase (CDK) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in... Agent: Sirna Therapeutics, Inc.

20090137500 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20090137510 - Rna interference mediated inhibition of nf-kappa b/ rel-a gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating NF-kappa B, REL-A, REL-B, REL, NKkappaB1, or NFkappaB2 gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways... Agent: Sirna Therapeutics, Inc.

20090137511 - Rna interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating placental growth factor (e.g., PGF-1 or PlGF-1, PGF-2 or PlGF-2, and/or PGF-3 or PlGF-3) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity... Agent: Sirna Therapeutics, Inc.

20090137508 - Rna interference mediated inhibition of polycomb group protein ezh2 gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of polycomb group protein... Agent: Sirna Therapeutics, Inc.

20090137509 - Rna interference mediated inhibition of proliferation cell nuclear antigen (pcna) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating PCNA gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PCNA gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090137519 - Semi-soft c-class immunostimulatory oligonucleotides: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.... Agent: Wolf Greenfield & Sacks, P.C.

20090137517 - Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding rps27l protein: The present invention refers to a method of sensitizing a cell to cancer treatment comprising modulating the activity of a nucleic acid which encodes the RPS27L protein by use of an oligonucleotide which is a RNAi agent or an antisense nucleotide molecule. The oligonucleotides of the present invention can be... Agent: Choate, Hall & Stewart LLP

20090137518 - Therapeutic antiangiogenic endostatin compositions: Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are provided.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090137520 - A1 adenosine receptor agonists: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.... Agent: Cv Therapeutics, Inc.

20090137521 - Certain compounds, compositions and methods: The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.... Agent: Arnold & Porter LLP (20595) Attn:IPDocketing Dept.

20090137522 - Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium: Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase... Agent: Colin P Abrahams

20090137523 - Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases: The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). Said composition contains adenosyl cobalamin (coenzyme B12), opt. in admixture with other cobalamins. Preferable said composition is present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.... Agent: Frommer Lawrence & Haug

20090137524 - Substituted arylpyrazoles: e

20090137525 - Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis: The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinaly tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions... Agent: Sutherland Asbill & Brennan LLP

20090137526 - Purification method for biomaterial: The present disclosure relates to methods for purifying chitin or chitosan, particularly for obtaining medical grade materials suitable for use in biocompatible devices,formulations, or other materials. Chitosan separation and purification methods are taught for obtaining high purity and fractionated bio-compatible medical grade materials. Chemistries and solvent systems are taught for... Agent: Life Microsystems Inc

20090137527 - Compositions and methods for modulating immune function: The invention relates to methods of modulating immune function, suppressing immune response, treating autoimmune diseases or autoimmune disorders, and treating diseases, sequelae or pathological conditions mediated by an activation of the immune system comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin... Agent: Ropes & Gray LLP

20090137528 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090137529 - Substituted esters as cannabinoid-1 receptor modulators: The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB 1) receptor. In particular, compounds of the present invention are 5 prodrugs of antagonists or inverse agonists of... Agent: Merck And Co., Inc

20090137530 - Amine compound and use thereof for medical purposes: wherein R is a hydrogen atom or P(═O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH═CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1... Agent: Birch Stewart Kolasch & Birch

20090137531 - Aryl amide sphingosine 1-: The present invention provides compounds that have antagonist activity at the S1P1 and/or S1P3 receptors. These compounds have enhanced selectivity and potency at the S1P1 and/or S1P3 receptors.... Agent: Iplm Group, P.A.

20090137532 - Aldolase-inhibiting aromatic compounds: The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two... Agent: Clark & Elbing LLP

20090137533 - Convenience kit for eyelid treatment: The present invention offers an eyelid treatment kit used for convenient combination therapy for improving overall eyelid hygiene while also providing for adjunctive eyelid therapy. The eyelid treatment kit comprises low dose doxycycline hyclate tablets, a non-irritating eyelid cleansing composition, an anti-bacterial eyelid preparation and at least one pair of... Agent: Jo Katherine D'ambrosio D'ambrosio & Associates, P.l.l.c.

20090137534 - Skin treatment compositions and methods: A skin treatment composition or cosmetic product comprising a) two or more active components, namely, at least one dermatological acid and at least one meroterpene and b) a dermatologically acceptable carrier.... Agent: Edward K. Welch Ii Ip&l Solution

20090137535 - Substituted oxazolidinone derivatives: This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090137536 - Method for treating and preventing hyperparathyroidism: This invention relates to a method for treating or preventing hyperthyroidism associated with aging and/or with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The invention further relates to treating or preventing one or... Agent: Michael Best & Friedrich LLP

20090137538 - Method of treating atrophic vaginitis: This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted... Agent: Wilmerhale/boston

20090137537 - Therapeutic gestagens for the treatment of premenstrual dysphoric disorder: A method of treating premenstrual dysphoric disorders comprising administering to a patient in need of such treatment daily from day 1 to day 24 3 mg of drospirenone and 0.02 mg of ethinylestradiol.... Agent: Millen, White, Zelano & Branigan, P.C.

20090137539 - Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.... Agent: Alcon

20090137540 - Compositions for the treatment of gastrointestinal inflammation: Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson Sonsini Goodrich & Rosati

20090137541 - Novel series of imidazolyl substituted steroidal and indan-1-one derivatives: The present invention provides a novel series of imidazolyl substituted steroidal and indan-1-one derivatives and salts thereof having the following general structural formulae (A and B)... Agent: Cooper & Dunham, LLP

20090137542 - Alpha-glucosidase inhibitors from fungal hydroxylation of tibolone and hydroxytibolones: Sixteen new and one known metabolites were obtained by incubation of tibolone and hydroxytibolones with various fungi. Their structures were elucidated by means of a homo and heteronuclear 2D NMR and by HREI-MS techniques. The relative stereochemistry was deduced by 2D NOESY experiment. These metabolites have shown promising inhibitory activities... Agent: Sarfaraz K. Niazi

20090137543 - Method and compounds for modulating insulin production: The present invention provides screening methods for the detection of agents that affect various aspects of β-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect β-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for... Agent: Dla Piper LLP (us)

20090137544 - Formation and rejuvenation of organs and alcohol damaged organ regeneration through stem cell nutrients: Mechanisms nourish stem cells for organ regeneration and prevent alcohol related diseases such as Fetal Alcohol Syndrome (FAS) and Liver Sclerosis. These stem cell nutrients have been found to positively affect the skin, liver, brain neurons, pancreas, and the GI tract. Cholesterol supplementation prevents fetal alcohol spectrum defects (FASD) in... Agent: Charles J. Prescott, P.A.

20090137546 - Anti-hypercholesterolemic compounds: This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.... Agent: Merck And Co., Inc

20090137547 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and... Agent: Amgen Inc.

20090137549 - Novel compounds useful for the treatment of degenerative & inflamatory diseases: The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.... Agent: Klauber & Jackson

20090137548 - 1,3-oxazolidin-2-one derivatives useful as cetp inhibitors: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to... Agent: Merck And Co., Inc

20090137545 - Compounds: wherein A, B, D, Y, R1, R2, R3, R4 and R5 are defined as in the specification, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090137550 - Novel compounds: This invention relates to a novel group of 8-Alkyl/Aryl-4-aryl-2-N-(alkylamino)-N″-substituted-N′-cyanoguanidino-8H-pyrido[2,3-d]pyrimidin-7-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090137551 - Substituted bicyclolactam compounds: i

20090137552 - Organic compound: The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions... Agent: Novartis Corporate Intellectual Property

20090137553 - Thiazepine oxazolidinones as antibacterial agents: The present invention relates to a new class of oxazolidinone derivatives, to their use as antibacterial agents, to pharmaceutical compositions containing these compounds and to methods for their preparation.... Agent: Pfizer Inc Steve T. Zelson

20090137554 - 1,4,5,6-tetrahydro -pyrrolo[2,3-d]azepines and -imidazo[4,5-d]azepines as modulators of nuclear receptor activity: and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR8, and S(O)2N(R9)R10; Y is chosen from CR11 and N; Z is chosen from O and NH; R3 is chosen from —C(O)R12 and —C(O)N(R9)R10; and n, R1, R2 and R4-R12 are defined herein; compositions comprising one or... Agent: Wyeth/finnegan Henderson, LLP

20090137555 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases and disorders associated with kinase activity, particularly diseases associated with the activity of CDK1, CDK2, CDK4, CDK5, GSK3β, Bcr-abl, Flt-3, c-Kit, PDGFRβ, Src, Mek1 and CK1.... Agent: Genomics Institute Of The Novartis Research Foundation

20090137556 - Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists: In one aspect, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of a dermatological disorder, particularly by topical application of said ACE inhibitor and/or angiotensin II receptor antagonist. The present invention also provides cosmetic... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090137557 - Calcilytic compounds: Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090137558 - Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products: The present invention relates to substituted pyridine compounds of Formula (I) and derivatives thereof, and to a process for preparing these substituted pyridines. The invention also relates to the use of the substituted pyridines as intermediates in the production of pharmaceutical, chemical and agro-chemical products.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090137559 - Bazedoxifene ascorbate: The present invention is directed to bazedoxifene ascorbate, compositions containing the same, dispersions thereof, preparations thereof, and uses thereof.... Agent: Wilmerhale/wyeth

20090137560 - Imidazole compounds having pharmaceutical activity towards the sigma receptor: e

20090137561 - Substituted biphenyl gpr40 modulators:

20090137562 - Substituted benzyl amine compounds: Certain substituted benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20090137564 - 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents: r

20090137563 - Process for the prepartion of olanzapine: The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]benzodiazepine (olanzapine) of the formula (I) by reacting 4-amino-2-methyl-10H-thieno [2,3-b][1/5]benzodiazepine hydrochloride of the formula (II) with N-methylpiperazine in an organic solvent, which comprises carrying out the reaction in the mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses new 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno... Agent: K.f. Ross P.C.

20090137565 - Method for treatment of movement disorders: The invention is directed to methods of treating movement disorders by administering an effective amount of the compound of formula (I) to patients in need thereof. More particularly, the invention is directed to a method for treating myoclonus including administering to a patient a compound of formula (I), wherein the... Agent: Wilmerhale/columbia University

20090137567 - Methods for treating blood disorders: Methods of treating blood disorders are described.... Agent: Swanson & Bratschun, L.L.C.

20090137566 - Substituted piperdines as renin inhibitors: t

20090137568 - Tryclic nitrogen containing compounds and their use as antibacterials: Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090137569 - Administration of (3s)-n-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (s)-n_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/affliction: i

20090137570 - Inhibitors of cathepsin s: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively... Agent: Genomics Institute Of The Novartis Research Foundation

20090137571 - Substituted morpholine and thiomorpholine derivatives: The present invention relates to morpholine and thiomorpholine derivatives or the general formula I or pharmaceutically acceptable salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090137573 - 1,3-disubstituted 4-methyl-1h-pyrrole-2-carboxamides and their use in medicaments: methods for their production, pharmaceutical compositions containing them, and the use thereof for noradrenalin receptor regulation, particularly for inhibiting noradrenalin reuptake, and/or for 5-HT receptor regulation, particularly for inhibiting 5-hydroxy tryptophan reuptake, and/or for opioid receptor regulation and/or for batrachotoxin (BTX) receptor regulation and/or for treating or inhibiting pain and... Agent: Crowell & Moring LLP Intellectual Property Group

20090137572 - 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders: The present invention relates to selected substituted pyrimidines their preparation, pharmaceutical compositions containing them and their use as inhibitors of one or more protein kinases, and hence their use in the treatment of proliferative disorders, viral disorders and/or other disorders.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090137574 - Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders: Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090137575 - Fused tetracyclic mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090137578 - Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments:

20090137577 - Heterocyclic compounds:

20090137576 - Novel piperidine derivative:

20090137579 - Mesylate salt of an ikk inhibitor: or a solvate thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (II), including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of a compound of formula (II), or crystalline forms thereof, for treating a patient... Agent: Millennium Pharmaceuticals, Inc.

20090137580 - Fused heterocyclic derivatives and use thereof: wherein ring A is an optionally substituted pyrrole ring, X is an optionally substituted CH, Y is an optionally substituted CH or nitrogen atom, Z is an optionally substituted divalent hydrocarbon group or optionally substituted divalent heterocyclic group, T is a single bond or an optionally substituted C1-3 alkylene group,... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090137581 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20090137582 - Pyrazolo-pyridinone derivatives and methods of use: wherein A1, A2, A3, A4, A5, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of inflammatory diseases including rheumatoid arthritis, psoriasis and other disorders, as well as intermediates and... Agent: Amgen Inc.

20090137583 - 2-aminoquinazoline derivatives: e

20090137585 - N-acylsulfonamide apoptosis promoters:

20090137584 - Sulfonyl benzimidazole derivatives: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2... Agent: Pfizer Inc.

20090137586 - Compounds for the treatment of inflammatory disorders: i

20090137587 - Phenylpyridone derivative: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they... Agent: Merck And Co., Inc

20090137588 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20090137589 - Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses: The present invention provides stereoisomers and stereoisomeric mixtures of 3-aminocarbonyl-bicycloheptene-2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090137590 - N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.... Agent: Metabolex, Inc.

20090137591 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPARδ.... Agent: Genomics Institute Of The Novartis Research Foundation

20090137592 - Morpholines as selective inhibitors of cytochrome p450 2a13: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090137593 - 4-amino-2,6-dimethylphenol compound, process for its preparation and pharmaceutical composition comprising the same: A 4-amino-2,6-dimethylphenol compound having the formula given in the description, acid-addition salts thereof, a process for preparing them, pharmaceutical composition comprising them and its use as anti-pyretic and anti-nociceptive agents.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090137594 - Pentafluorosulphanyl-substituted compound and its use for producing medicaments: The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20090137595 - Fused heterocyclic derivative and use thereof: wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090137596 - G-protein inhibitor: e

20090137598 - Method of treating metabolic disorders and depression with dopamine receptor agonists: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.... Agent: Darby & Darby P.C.

20090137599 - Methods of identifying responders to dopamine agonist therapy: The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090137597 - Novel quinoxalinone derivatives: e

20090137600 - Antiplatelet agent and process for producing the same: A compound having an action of suppressing platelet aggregation is provided. This compound also exhibits excellent physical properties and oral absorbability. This compound is represented by formula (Ib): Its production method is also provided.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090137601 - L-phenylalanine derivatives: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of... Agent: Astrazeneca R&d Boston

20090137602 - Combination preparation against vertigo: The use of cinnarizine and dimenhydrinate or their physiologically compatible salts in combination is described for the treatment of vertigo of any genesis.... Agent: Kriegsman & Kriegsman

20090137603 - Heterocyclic amide compound and use thereof: e

20090137604 - Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient:

20090137605 - Polymorphic forms of ziprasidoneand its hydrochloride salt and process for preparation thereof: The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of... Agent: Dr. Reddy''s Laboratories, Inc.

20090137606 - Chewable formulations: The invention encompasses a solid dose pharmaceutical composition comprising a disagreeable-tasting drug and processes for preparation of the pharmaceutical composition. The pharmaceutical composition is designed not to be swallowed immediately.... Agent: Kenyon & Kenyon LLP

20090137608 - Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor: Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for H4 receptor activity modulation and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20090137607 - Fused bicyclic pyrimidines: n

20090137611 - Fungicide n-cyclopropyl-sulfonylamide derivatives: The present invention relates to N-cyclopropyl-sulfonylamide derivatives of formula (I) wherein the substituents are cyclic groups, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions: (I)... Agent: Ostrolenk Faber Gerb & Soffen

20090137610 - Spiro imidozole derivatives as ppar modulators: The invention provides compounds (Ia), (Ib) and (Ic), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.... Agent: Genomics Institute Of The Novartis Research Foundation

20090137609 - Vitamin d-like compound: or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis,... Agent: Darby & Darby P.C.

20090137612 - Treatment with combined use of oxypurines and ascorbate to prevent and mitigate iron-catalized oxidative damage in alzheimer's disease and other neurodegenerative disorders: A method is provided for the prevention and treatment of selective progressive degeneration within the central nervous system caused by hydroxyl-free or ferryl-free radicals formed by Fenton-type catalyzed reactions between diffusible hydrogen peroxide and localized bivalent iron. The invention embodies unique pharmacologic composition for antioxidant protection by oral supplementation with... Agent: Lynn E Barber

20090137613 - Pharmaceutically acceptable salts and polymorphic forms: The present invention is concerned with new pharmaceutically acceptable salts of valacyclovir, polymorphic forms, processes for preparing the new pharmaceutically acceptable salts and new polymorphic forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same.... Agent: Foley & Lardner LLP

20090137615 - Indazolylamino quinazoline derivatives as antitumour agents: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.... Agent: Morgan Lewis & Bockius LLP

20090137614 - Pharmaceutical combination comprising vitamin k: It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090137616 - Method for the control of phytopathogenic fungi: The present invention provides a method of controlling Pythium infection of plants comprising treating the plant or plant propagation material with a strobilurin, in particular, wherein the Pythium species is phenylamide insensitive. In addition, the present invention provides for use of a strobilurin for control of Pythium infection of a... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090137617 - Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease: This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a... Agent: Pearl Cohen Zedek Latzer, LLP

20090137618 - Pro-drugs for controlled release of biologically active compounds: Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a biologically active compound.... Agent: Viksnins Harris & Padys Pllp

20090137619 - Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent: A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said... Agent: Nixon & Vanderhye, PC

20090137620 - Use of gallium(iii) complexes for the treatment of melanomas: The invention relates to the use of gallium (III) complexes for the treatment of melanomas.... Agent: Perkins Coie LLP

20090137621 - Capsules containing inhalable tiotropium: The invention relates to capsules for inhalation (inhalettes) made from specific capsule materials with a reduced moisture content, which contain the active substance tiotropium in the form of powdered preparations and are characterised by increased stability.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090137622 - Use of pyrroloquinoline compounds to kill clinically latent microorganisms: e

20090137623 - Muscarinic receptor antagonists: The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition... Agent: Ranbaxy Inc.

20090137624 - Chemical compounds: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.... Agent: Astrazeneca R&d Boston

20090137625 - Novel enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors: i

20090137627 - Method for treating chronic pain: A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.... Agent: Olson & Cepuritis, Ltd.

20090137626 - Pharmaceutical composition containing ppargamma agonist: m

20090137628 - Formulations of indanylamines and the use thereof as local anesthetics and as medication for chronic pain: Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine and capsaicin are also provided.... Agent: Nields, Lemack & Frame, LLC

20090137629 - Sigma receptor binding agent containing indanone derivative: r

20090137630 - Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis: The compounds of this type are of useful in the treatment of various disorders, such as, respiratory disorders and snoring, acute and chronic disorders, disorders induced by ischemic and/or reperfusion events and by proliferative or fibrotic events, disorders of the central nervous system and lipid metabolism, diabetes, blood coagulation and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090137631 - Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression: Methods and pharmaceutical compositions for regulations of Guanosine- (G-) and/or Guanosine-cytosine-rich (GC-rich) nucleic acid expressions are provided. The methods include a step of interacting the G- and/or GC-rich region of the nucleic acid with thalidomide, and the pharmaceutical compositions include the thalidomide and a pharmaceutical carrier.... Agent: Ipc Intellectual Property Connections, Inc.

20090137632 - Compositions and methods for treating dyslipidemia: The present invention provides a method for treating dyslipidemia in a mammal, comprising administering to a mammal in need thereof, an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or solvate thereof and at least one statin.... Agent: Eli Lilly & Company

20090137634 - Pest control agents: Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090137633 - Stable pharmaceutical composition of rabeprazole: The present invention relates to a method of preparing a stable pharmaceutical composition of rabeprazole. The preparation may be used as an injectable dosage form in the treatment of severe gastric ulcers.... Agent: Darby & Darby P.C.

20090137635 - Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators: e

20090137636 - Reverse isoxazoles: The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090137637 - Tetrazolyl-methylene amino acid derivatives: This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, R2a, L1,... Agent: Pfizer Inc.

20090137638 - Thiazolidinedione analogues: The present invention relates to thiazolidinedione analogues that are useful for treating hypertension.... Agent: Honigman Miller Schwartz & Cohn LLP

20090137639 - Methods for controlling fungi and bacteria: The present invention includes compounds of pyridinium salts and methods of their use for agricultural purposes. The present invention also relates to methods of controlling fungi and/or bacteria.... Agent: Myers Bigel Sibley & Sajovec

20090137640 - Potentiator for radiation therapy comprising pyridine derivative as active ingredient: wherein R1, R2, and R4 may be the same or different from one another and represent a hydrogen atom, hydroxy group, or protected hydroxy group, excluding the case where R1, R2, and R4 are all a hydrogen atom, and R3 represents a halogen atom, amino group, carboxyl group, carbamoyl group,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090137641 - Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms: The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost.... Agent: Beusse Wolter Sanks Mora & Maire

20090137642 - 2-acylaminothiazole derivatives: The Invention relates to compounds of the formula I, wherein the variables are as defined in the claims, for use as a medicament. The compounds are A2A-receptor legends and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090137643 - Methods for inhibiting or reversing tau filament fibrillization: Methods for inhibiting and/or reversing tau filament formation or fibrillization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or fibrillization. A preferred composition comprises 3-(2-hydroxyethyl )-2-[2-[[3-(2-hydroxyethyl )-5-methoxy-2-benzothiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium.... Agent: Fitch Even Tabin And Flannery

20090137644 - Rhodanine compositions for use as antiviral agents: This invention describes compounds and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating diseases caused by viruses such as... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090137645 - Shelf-stable famotidine granulates for oral suspensions: A granulate for oral suspension that is particularly useful for the storage and reconstitution of famotidine into a liquid suspension.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090137646 - 1,2 benzoisothiazole derivative, and agricultural or horticultural plant disease- controlling agent: g

20090137647 - Modified macrophage migration inhibitory factor inhibitors: Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in... Agent: Amster, Rothstein & Ebenstein LLP

20090137648 - Process for the preparation of irbesartan hydrochloride: The present invention is concerned with a process for the preparation of 2n-butyl-4-spirocyclopentane-1-[(2′-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolin-5-one hydrochloride, irbesartan hydrochloride, novel hydrated and anhydrous crystalline forms thereof, amorphous irbesartan hydrochloride, formulations containing the same, therapeutic uses thereof and methods of treatment employing the same. The process of the present invention is a one-pot process... Agent: Conley Rose, P.C.

20090137649 - Concentrated liquid triazole-fungicide formulations: Concentrated liquid formulations of triazole fungicides are provided and the use of such formulations in diluted form for the control of harmful fungi. The formulations are both storage stable and prevent crystallization of the triazole fungicide when applied in diluted form.... Agent: Jacobson Holman PLLC

20090137652 - Methods for neuroprotection: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20090137650 - New compounds: e

20090137651 - Pharmaceutical composition for external use: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.... Agent: Knobbe Martens Olson & Bear LLP

20090137653 - Substituted benzylamines as cyp2a inhibitors and uses thereof to treat nicotine dependence: This invention is directed to substituted benzylamines which are useful as inhibitors of the CYP2A6 enzyme. Pharmaceutical compositions comprising the compounds and methods of using the compounds to treat nicotine dependence are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20090137654 - Methods of modulating binding of son of sevenless to phosphatidic acid and identifying compounds that modulate such binding: The present invention relates to methods of modulating binding of Son of sevenless to phosphatidic acid and identifying compounds that modulate such binding. In particular, the present invention relates to a method of controlling pleckstrin homology domain-dependent membrane recruitment of Son of sevenless or histone folds domain-dependent membrane recruitment of... Agent: Nixon Peabody LLP - Patent Group

20090137655 - Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof: The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression,... Agent: Fish & Richardson P.C.

20090137657 - External liquid preparation containing indomethacin: e

20090137656 - Intermolecular association complex of a carrier and of an active principle: The invention relates to an intermolecular association complex of formula (I) of an amphiphilic carrier and of an active principle Z-Y, in which; S, X n, R1, R2, R3, Y, Z are as defined in the description.... Agent: Birch Stewart Kolasch & Birch

20090137658 - Benzenesulfonic acid salt compounds: Besylate salts of trans-4-({2-[(2S)-2-cyano-pyrrolidinyl]-2-oxoethyl}amino)-N,N-dimethylcyclohexanecarboxamide are described as well as methods of using the same in the treatment of disorders characterized by hyperglycemia.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090137659 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Wilson Sonsini Goodrich & Rosati

20090137660 - Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or... Agent: Nixon & Vanderhye, PC

20090137661 - Plant derived compounds and compound formulae containing the same for the treatment of cervical cancer: A composition for reducing the activity of a cervical cancer cell is provided. The composition includes at least one of the following compounds: isopsoralen, triptolide, baicalein, gallic acid, quercetin, gossypol-acetic acid, baicalin, berberine hydrochloride, and derivatives thereof in a sufficient amount to reduce the activity of the cervical cancer cell... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20090137662 - Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers: This invention pertains to the discovery that a dopamine receptor agonist can activate PKA signaling and/or can act synergistically with an adenosine receptor to activate such signaling. In various embodiments, this invention exploits the synergy between the dopamine receptor pathway and an adenosine receptor pathway to provide methods of mitigating... Agent: Jones Day

20090137663 - Therapeutic micro nutrient composition for drug delivery: A lecithin based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. The formulation is characterized in that it comprises an adjustable buffer, an antoxidant, and a stabilizer. It is further characterized in that it includes liposomes, and that the components of these liposomes... Agent: Teresa Ann Denney # 525

20090137664 - Saururus cernuus compounds that inhibit cellular responses to hypoxia: Compounds and compositions that effectively block hypoxia-inducible factor-1 function, and methods of use thereof. The compounds and compositions of the present invention are useful in the prevention and treatment of cancer, stroke, heart disease, ocular neovascular diseases, and arthritis.... Agent: Stites & Harbison PLLC

20090137665 - Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase: A method of neuroprotection which comprises administration of an AMPK inhibitor to a patient who is experiencing or has experienced a stroke, the compound being an AMPK inhibitor. Treatments with these agents significantly reduce the size of infarcts, and therefore minimize the loss of brain tissue and neurons. Thus, function... Agent: Jacobson Holman PLLC

20090137666 - Fluorescent particles comprising nanoscale zno layer and exhibiting cell-specific toxicity: Multifunctional “smart” nanostructures are disclosed that include fluorescein isothiocyanate (FITC)-encapsulated SiO2 core-shell particles with a nanoscale ZnO finishing layer, wherein an outer ZnO layer is formed on the SiO2-FITC core. These ˜200 nm sized particles showed promise toward cell imaging and cellular uptake studies using the bacterium Escherichia coli and... Agent: Pedersen & Company, PLLC

20090137667 - Pesticide delivery system: An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphiphilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a pesticide. Compositions based on the microblend and methods of using the compositions to control pests are... Agent: Patent Administrator Fmc Corporation

20090137668 - C-nitroso-derived nitroxyl donors: Active compounds of Formula (I) are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.... Agent: Myers Bigel Sibley & Sajovec

20090137669 - Creatine ester anti-inflammatory compounds and formulations: The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the... Agent: Dann, Dorfman, Herrell & Skillman

20090137670 - Amino acid compounds: Carnitine and Taurine Compounds are described. The Carnitine Compound comprises Carnitine and one of a Nitrate and a Nitrite. The Taurine Compound comprises Taurine and one of a Nitrate and a Nitrite.... Agent: Booth Udall, PLC

20090137671 - Methods of treating metabolic disorders: A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β/δ of the cells.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090137672 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137673 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137674 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137675 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137676 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137677 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090137678 - High yield synthesis methods for producing organic salts of strontium: New organic salts of strontium and methods of synthesizing such salts with high purity, high yields and with short processing times, at neutral conditions and at low reaction temperature, such as a temperature at or below 50° C.... Agent: Jones Day

20090137679 - Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors: Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.... Agent: Calfee Halter & Griswold, LLP

20090137680 - Novel non-selective cation channel in neuronal cells and method for treating brain swelling: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is... Agent: Fulbright & Jaworski, LLP

20090137681 - Sirtuin inhibiting compounds: Provided herein are compositions and methods for treating or preventing cancer and autoimmune diseases. Compositions comprise a sirtuin inhibitory compound that decreases the activity of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell or a molecule with a sirtuin inhibitory compound that decreases the activity... Agent: Wolf Greenfield & Sacks, P.C.

20090137682 - Combination cancer therapy with bis(thiohydrazide) amide compounds: A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090137683 - Anticancer effect enhancer: An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric... Agent: Kratz, Quintos & Hanson, LLP

20090137684 - Sustained-release preparations and method for producing the same: The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparations according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its... Agent: Jones Day

20090137685 - Therapeutic agent for inflammatory bowel disease containing as active ingredient 2-amino-1,3-propanediol derivative, or method for treating inflammatory bowel disease: e

20090137686 - Treatment of ophthalmic diseases: Beta-amino alcohols are useful for the treatment of ophthalmic conditions.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090137687 - Compositions and methods with enhanced therapeutic activity: This invention relates to novel tricyclic quinone and catechol compositions, compositions containing prodrugs of tricyclic quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. In certain aspects, the compositions of the invention are capable of generating both a vascular... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090137688 - Pharmaceutical product: The present invention relates to a pharmaceutical product comprising porous silicon, a beneficial substance, and an excipient, the beneficial substance being located in at least some of the pores of the porous silicon, and the excipient having a structure and composition such that it has a melting point between 25... Agent: Nixon & Vanderhye, PC

  
05/21/2009 > patent applications in patent subcategories. archived by USPTO category

20090131302 - Transient receptor potential vanilloid 1 and uses thereof: The present invention describes methods of retarding the development of visceral and somatic hypersensitivities in an individual. Further, the present invention describes a potentially important role for the transient receptor potential vanilloid 1 (TRPV1) in initiation and maintenance of the chronic visceral hypersensitivity and its role in development of irritable... Agent: Benjamin Aaron Adler Adler & Associates

20090131303 - Methods and compositions for treating dry eye: The present invention is directed to ophthalmic compositions containing protease-inhibiting peptide substrates. In a preferred embodiment, the protease-inhibiting peptide substrate is gelatin. The compositions may also contain a galactomannan. In a particularly preferred embodiment, the compositions contain gelatin, a galactomannan and a borate salt. The present invention also describes methods... Agent: Alcon

20090131305 - Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases: The present invention relates to methods for the treatment of exacerbation periods of pulmonary diseases, particularly chronic obstructive pulmonary diseases, by administering alpha-1 antitrypsin (AAT) to a subject in need thereof. Particularly, the present invention discloses the efficient treatment of exacerbation periods of pulmonary diseases by administering AAT via inhalation.... Agent: Winston & Strawn LLP Patent Department

20090131304 - Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides.... Agent: Weaver Austin Villeneuve & Sampson LLP

20090131306 - Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor: Chemically modified cyclic peptides comprising cell adhesion recognition (CAR) sequences are provided having improved properties, such as improved stability. Also provided are methods of making and using same.... Agent: Seed Intellectual Property Law Group PLLC

20090131307 - Pharmaceutical compositions comprising cyclosporins: A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.... Agent: Allergan, Inc.

20090131317 - Compounds and peptides that bind the trail receptor: The present invention relates to peptides and compounds that bind to a TRAIL receptor or otherwise act as a TRAIL receptor agonist, as well as methods of treating human diseases using the same. In addition, methods of synthesizing the peptides and compounds described herein are provided by the present invention.... Agent: Darby & Darby P.C.

20090131316 - Glucagon-like peptide-1 secretagogue, glucagon-like peptide-1 secretagogue food or drink, inhibitor of postprandial rise in blood glucose, and inhibitory food or drink of postprandial rise in blood glucose: The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing κ-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein κ-casein... Agent: Wood, Herron & Evans, LLP

20090131319 - Human tumor necrosis factor receptor-like 2: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090131309 - Ica512 couples insulin secretion and gene expression in beta-cells: The present invention relates to a method for stimulating expression of peptide hormones in peptide-hormone secreting endocrine cells or neurons comprising the step of promoting in said cells or neurons the presence or activity (aa) of (i) ICA512; or (ii) a derivative thereof having ICA512 function; or (iii) a fragment... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090131313 - Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage: A pharmaceutical, ophthalmic or cosmetic combination or method utilizes a peptide agent include amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and further utilizes a quaternary ammonium salt, wherein the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090131311 - Method for preventing formation of trisulfide derivatives of polypeptides: A method for reducing or substantially preventing formation of a trisulfide derivative of a polypeptide in a liquid medium containing the polypeptide ijn question comprises stripping the liquid medium with a gas, suitably a chemically unreactive gas such as nitrogen or argon.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090131310 - Mucin3 egf-like domains: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGF-like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20090131312 - Non-natural chemokine receptor ligands and methods of use thereof: The present invention provides non-natural CXCR3 ligands comprising the N-loop region of the iTAC and polynucleotide encoding such non-natural CXCR3 ligands. The invention additionally provides methods of treating fÊbrotic disorders, angiogenic disorders, and cancer. The methods generally involve administering to an individual in need thereof an effective amount of a... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090131318 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: K&l Gates LLP

20090131308 - Splice variants of erbb ligands, compositions and uses thereof: The present invention relates to nucleic acid and amino acid sequences of previously unknown ErbB ligands that are splice variants of previously known ErbB ligands, to compositions comprising these sequences and uses thereof in the diagnosis, treatment, and prevention of diseases and disorders mediated by ErbB receptors. Specifically, the present... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090131314 - Thrombospondin-1 derived peptides and treatment methods: Treatments employing the matricellular protein thrombospondin-1 (TSP-I) and related compositions are disclosed for stabilizing atherosclerotic plaque and decreasing occurrence of plaque rupture events leading to, for example, myocardial infarction, stroke, and acute limb ischemia. Various peptides, including certain synthetic peptides, related to TSP-I are also disclosed. Such peptides have utility... Agent: Iphorgan, Ltd.

20090131315 - Treatment of subarachnoid hemorrhage with apo e analogs: Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090131320 - Peptides modulating the activity of the engrailed transcription factor: The invention relates to peptides which can become fixed to the engrailed transcription factor and which can modulate the activity thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090131322 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131323 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131324 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131325 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131326 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131321 - Method of reducing injury to mammalian cells: A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein.... Agent: Townsend And Townsend And Crew, LLP

20090131327 - Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same: The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) and use of peptides mimicking these functional motifs as antagonists to NgR1 ligands, e.g., myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A, Nogo-66, an antibody to Nogo receptor, an antibody to... Agent: Fitzpatrick Cella Harper & Scinto

20090131328 - Furin inhibitors: Inhibitors for the endoprotease furin are provided for the prevention, diagnosis, treatment, and study of human and animal pathologies, which involve furin activity. These pathologies include infections caused by bacteria and virus that exploit host furin activity. These pathologies also include diseases that involve the expression of host proproteins that... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090131329 - Treatment for allograft rejection: Provided are methods of treating a mammal at risk for allograft rejection. The methods comprise treating the mammal with a compound that reduces an interaction between a CXC chemokine and a CXC receptor.... Agent: Amster, Rothstein & Ebenstein LLP

20090131332 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131333 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131334 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131335 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131331 - Novel nutraceutical compositions: The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament.... Agent: Nixon & Vanderhye, PC

20090131330 - Par-2 agonist: Disclosed is a compound represented by the following general formula (1): Ar—CO-AA1-AA2-AA3-AA4-NH—X—NR1R2 (1) (wherein Ar represents an optionally substituted phenyl group or an aromatic heterocyclic group; AA1 represents a hydrophobic amino acid; AA2 represents an unsubstituted amino acid containing 2 or more carbon atoms; AA3 represents an unsubstituted amino acid... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090131337 - Hair growth composition: The present invention provides a hair growth agent having novel action mechanism and a hair growth composition containing the agent. Specifically, the present invention provides a novel hair growth composition containing one or more kinds of epsilon-N-(gamma-glutamyl)lysine or a salt thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090131336 - Isoxazole derivatives and use thereof: Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.... Agent: Gibbons P.C.

20090131338 - Anesthesia arousal composition: A method for facilitating postoperative awakening of patients from anesthesia does not depend on the experience of anesthesiologists. Also provided are an anesthesia arousal composition for use in this method and a preparation containing a bicarbonate ion that facilitates awakening from anesthesia. Specifically, the anesthesia arousal composition is provided in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090131339 - Compounds having neuroprotective properties: The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.... Agent: Intellectual Property / Technology Law

20090131340 - Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations: A method of treating or prophylactically treating immunosuppression or allergic and inflammatory symptoms of skin caused by UVB radiation which comprises applying to the skin a cosmetic or dermatological composition which comprises one or more flavonoids.... Agent: Greenblum & Bernstein, P.L.C

20090131341 - Novel dihydropseudoerythromycin derivatives: A compound represented by the formula [I] wherein each symbol is as defined in the specification or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing the compound as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090131342 - Nitrosated and/or nitrosylated compounds, compositions and methods of use: The invention describes novel nitrosated and/or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions... Agent: Wilmerhale/nitromed

20090131343 - Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases: The invention provides methods utilizing bridged macrolide or tylosin derivatives for the treatment of patients with inflammatory bowel diseases. The methods of the invention provide for the administration to a patient of a therapeutically effective amount of a bridged macrolide or a tylosin derivative, pharmaceutically acceptable derivatives thereof, and combinations... Agent: Elmore Patent Law Group, PC

20090131344 - Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives: This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous... Agent: Rashida A. Karmali

20090131346 - Antibody and method for identification of dendritic cells: Method for identifying myeloid or plasmacytoid dendritic cells provided by a mammal, stimulated or unstimulated, comprising the steps of: a) preparing a cell sample; b) contracting the cell sample myeloid or plasmacytoid dendritic cells to form a complex; c) detecting the complex; characterized in that the phosphatase is the Receptor... Agent: Greenberg Traurig LLP (la)

20090131359 - Antifibrotic therapy: The present invention relates to methods of treating severe or rapidly progressing pulmonary fibrosis in a subject in need of a treatment thereof. The methods comprise increasing the activity of pulmonary and activation-regulated chemokine (CCL18) in the lungs of the subject, whereby increasing CCL18 activity modulates the activity of at... Agent: Morgan Lewis & Bockius LLP

20090131352 - Aptamers comprising arabinose modified nucleotides: Nucleic acid ligands (or aptamers) that form a G-tetrad containing at least one arabinose modified nucleotide are provided. Preferably, the arabinose modified nucleotide is 2′-deoxy-2′-fluoroarabinonucleotide (FANA) nucleotide. Methods of using aptamers the aptamers of the claimed invention are also provided.... Agent: Pepper Hamilton LLP

20090131357 - Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090131353 - Diagnosis and treatment of chronic lymphocytic leukemia (cll): The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes... Agent: Sutherland Asbill & Brennan LLP

20090131350 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090131347 - Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype: The invention relates to methods for preventing or reducing antigen-stimulated, granulocytemediated inflammation in tissue of an antigen-sensitized mammal host by delivering an immunostimulatory oligonucleotide to the host. In addition, methods for using the immunostimulatory oligonucleotides to boost a mammal host's immune responsiveness to a sensitizing antigen (without immunization of the... Agent: Bozicevic, Field & Francis LLP

20090131358 - Low density lipoprotein receptor-mediated sirna delivery: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are... Agent: Alcon

20090131345 - Medicament and method for treating recurrent spontaneous abortion: The present invention discloses a pharmaceutical composition for treating a subject with immunological recurrent spontaneous abortion which comprises a therapeutically effective amount of a substance capable of lowering the in vivo level of antinuclear antibody. Particularly, the substance is chromosome No. 2 or fragment thereof containing fibronectin encoding gene derived... Agent: Ladas & Parry LLP

20090131349 - Methods and compositions for modulating body weight and for treating weight disorders and related diseases: Methods of modulating body weight and/or fat content of a subject, methods of treating or preventing weight disorders and methods of treating or preventing weight disorder related diseases are disclosed. The methods include modifying an activity or expression of a protein tyrosine phosphatase epsilon (PTPe) so as to modulate the... Agent: Martin D. Moynihan Prtsi

20090131351 - Methods, compositions, and kits for modulating tumor cell proliferation: The present invention relates to compositions, methods, and kits for modulating tumor proliferation using G-rich oligonucleotides and one or more chemotherapeutic agents.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090131348 - Micrornas differentially expressed in pancreatic diseases and uses thereof: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.... Agent: Fullbright & Jaworski L.L.P.

20090131354 - Mir-126 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-126, using miR-126 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090131356 - Mir-15, mir-26, mir-31, mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3p, and using nucleic acid comprising all or part of the miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3p sequences to modulate a gene... Agent: Fullbright & Jaworski L.L.P.

20090131355 - Multicistronic vectors and methods for their design: Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein... Agent: Davis Wright Tremaine LLP/mankind Corporation

20090131361 - Novel use of mln51 gene and protein: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis, particularly chronic synovitis.... Agent: Clark & Elbing LLP

20090131360 - Tripartite rnai constructs: The present invention provides compositions and methods for inhibiting expression of a target gene in a cell. The process comprises introduction of double-stranded tripartite RNAi constructs into the cells and reducing the expression of the corresponding messenger RNA in the cells. The constructs, which may be packaged in or delivered... Agent: Ropes & Gray LLP

20090131362 - Use of defibrotide for the inhibition of heparanase: A study has been carried out to verify the effect of Defibrotide on the activity and expression of Heparanase enzyme on myeloma tumor cells (U266) and human microvascular endothelial cells (HMEC). The study has demonstrated that defibrotide can be effectively used for the manufacture of a medicament for the treatment... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20090131363 - Deuterated darunavir: This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090131364 - Bioactive fraction from zingier officinale and a process for the preparation thereof: Ulcer is a serious oxidative stress induced disease with complex pathologic events including upregulation of H+K+ ATPase of parietal cell (PC) membrane, damage of mucin layer around PC, PC-DNA damage etc. The polysaccharide (GRPP) fraction and antioxidant extract (GRAOX) of ginger was examined for their ability to inhibit H+ K+... Agent: Ladas & Parry LLP

20090131365 - Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms): The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20090131367 - Combinations of hdac inhibitors and proteasome inhibitors: Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of cancer.... Agent: Wilson Sonsini Goodrich & Rosati

20090131366 - Use of amine-borane compounds as anti-microbial agents: Use of amine-borane compounds such as amine cyanoboranes and amino carboxy boranes in the treatment of medical conditions associated with pathogenic microorganisms and particularly against drug-resistant microorganisms, in the treatment of fungal and protozoal infections is disclosed. Use of amine-borane compounds for reducing the load of microorganisms in various substrates... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090131368 - Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species: A chemical composition of a molecular species mixture of phospholipids, purified to at least 85% purity through chromatography purification, the chemical composition contains enriched both sn-1-acyl fatty chains/sn-2-docosahexaenoic acid molecular species and sn-1-ether fatty chains/sn-2-docosahexaenoic acid molecular species, the phospholipids are selected from the group consisting of: phosphatidylcholine, phosphatidylserine and... Agent: Law Office Of Michael A. Blake, LLC

20090131369 - Novel benzimidazole(thio)carbamates with antiparasitic activity and the synthesis thereof: Here, X1 and X2 are independently O or S, wherein at least one of X1 and X2 is O; Y1 and Y2 are independently O or S, wherein at least one of Y1 and Y2 is O; R1 is alkyl having from 1-4 carbon atoms; R2, R3, and R4 are... Agent: Intervet/schering-plough Animal Health Patent Department

20090131370 - Novel nucleoside derivatives: Compounds of Formulae I-XVI, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and other diseases are described: formula (I).... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090131371 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090131372 - Phosphonate analogs for treating metabolic diseases: The invention is related to phosphorus substituted compounds with activity for treating metabolic diseases and/or disorders, e.g., diabetes and hypercholesterolemia, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090131373 - Phospholipid complexes of curcumin having improved bioavailability: The present invention relates to novel phospholipids complexes of curcumin or extracts containing it having improved bioavailability.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090131374 - Protein tyrosine phosphatase inhibitors and methods of use thereof: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions... Agent: Merchant & Gould PC

20090131375 - Composition and method for treating skin: A method for the topical treatment of skin aging and acne and the improvement of skin appearance is disclosed. Compositions for use in this method and a kit containing such compositions are also disclosed. In some of the embodiments of the invention, either one, or both, of the acid composition... Agent: Kenyon & Kenyon LLP

20090131377 - Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs: Combinations of synthetic low molecular weight catalysts for the dismutation of superoxide and Nonsteroidal Analgesic/Anti-Inflammatory Drugs (NSAIDs) are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090131376 - Process for the modification of the solid state of a compound and co-amorphous compositions produced with same: The invention provides a process for preparing non-crystalline organic compositions and non-crystalline, co-amorphous blends of organic compounds.... Agent: Kenyon & Kenyon LLP

20090131378 - Vitamin d derivatives active on the vitamin d nuclear receptor, preparation and uses thereof: The invention relates to vitamin D derivatives and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having different interesting biological properties, including vitamin D nuclear receptor (VDR) agonist activity, as well as therapeutics methods by administering said compounds, in particular for treating cancer, psoriasis, autoimmune diseases, osteodistrophy... Agent: Hunton & Williams LLP Intellectual Property Department

20090131379 - Vitamin d receptor activators and methods of making: The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.... Agent: Paul D. Yasger Abbott Laboratories

20090131381 - Compositions comprising hydroquinone, fluocinolone acetonide and tretinoin for treating photoaging of the skin: Dermatological/medicament compositions containing a combination of hydroquinone, fluocinolone acetonide and tretinoin are useful for treating the signs of photoaging of the skin.... Agent: Buchanan, Ingersoll & Rooney PC

20090131380 - Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof: The present invention provides the combination of topical 3,3,′5,5′-tetraiodothyroacetic acid and betamethasone for the treatment of skin psoriasis results in a better outcome than the combination of topical calcipotriol and betamethasone. The present invention also provide a method for treatment of skin psoriasis by using the composition of 3,3,′5,5′-tetraiodothyroacetic acid... Agent: Jacobson Holman PLLC

20090131382 - Treatment of rheumatoid arthritis using imatinib: e

20090131384 - Compounds and methods for treatment of disorders associated with er stress: The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.... Agent: Edwards Angell Palmer & Dodge LLP

20090131383 - Pharmaceutical compositions of a neuroactive steriod and methods of use thereof: The present invention relates to pharmaceutical compositions of the neuroactive steroid 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, with properties desirable for use in treating mood disorders and the like. The pharmaceutical compositions provide sustained therapeutic plasma levels of 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one. The present invention also relates to methods of treating... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090131386 - Compositions for the treatment of inflammation of the gastrointestinal tract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson Sonsini Goodrich & Rosati

20090131385 - Estriol therapy for autoimmune and neurodegenerative diseases and disorders: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, neurodegenerative diseases or disorders, such as Alzheimer's disease, Parkinson's Disease, multiple sclerosis, stroke, ALS Pick's disease, prion disease and Huntington's disease. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent... Agent: Mcdermott, Will & Emery LLP Attn:IPDepartment

20090131387 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090131388 - Agent for improving insulin resistance: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance or ameliorate the pathosis, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent... Agent: Knobbe Martens Olson & Bear LLP

20090131389 - Preparation of a crystalline antibiotic substance: The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment... Agent: Birch Stewart Kolasch & Birch

20090131390 - Fk 228 derivates as hdac inhibitors: Compounds which are FK228 analogues of the general formula (I) or (I′), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3 and R4 are the same or different and represent an amino acid side chain moiety and each R6 is the same or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090131391 - Inhibitor for differentiation of hematopoietic precursor cells: The invention relates to medicine and can be used for treating persons with diseases associated with a differentiation of hematopoietic precursor cells. The inventive inhibitor for differentiation of hematopoietic precursor cells is embodied in the form of an organic compound of selen-9-phenyl-symmetrical-octahydro-selenoxanten. Said agent makes it possible to more efficiently... Agent: Houston Eliseeva

20090131392 - Phtalocyanine derivatives, process for their preparation, pharmaceutical compositions containing them and their use: Phthalocyanine derivatives are described having photosensitising characteristics and high solubility in water, useful for photodynamic treatment of bacterial infections, in particular infections generated by Gram-negative bacteria.... Agent: Knobbe Martens Olson & Bear LLP

20090131393 - Process for preparing chlorides of phthalocyanine derivatives comprising at least a quaternary ammonium group: A process is described for preparing chlorides of phthalocyanine derivatives comprising at least a quaternary ammonium group, products useful as photosensitising agents in photodynamic therapy.... Agent: Knobbe Martens Olson & Bear LLP

20090131394 - Broad spectrum beta-lactamase inhibitors: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting... Agent: Greenlee Winner And Sullivan P C

20090131395 - Biphenylazetidinone cholesterol absorption inhibitors: o

20090131396 - Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies: Administration of sPLA2 inhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLA2 inhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore,... Agent: Perkins Coie LLP

20090131398 - Oxindole derivative as feeding control agent: (In the formula, R3 represents an optionally substituted carbamoyl group or the like; X represents a hydroxyl group or the like; W1 and W2 independently represent a single bond or methylene; R7 and R8 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; and Ar represents... Agent: Birch Stewart Kolasch & Birch

20090131397 - Estrogen modulators: The present application is directed to a new class of isoxazoles and their use as estrogen modulators.... Agent: Pfizer Inc.

20090131399 - Imidazopyridine derivatives useful as inos inhibitors: e

20090131400 - Immunosuppressant compounds and compositions: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.... Agent: Genomics Institute Of The Novartis Research Foundation

20090131403 - Nitrogenated heterocyclic derivative , and pharmaceutical agent comprising the derivative as active ingredient: e

20090131402 - Fused heterocyclic compound and use thereof: wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090131401 - Transcription factor modulating compounds and methods of use thereof: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090131404 - Combinations: The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) HMG-Co-A reductase inhibitors or a pharmaceutically acceptable salt thereof; and (ii)... Agent: Novartis Corporate Intellectual Property

20090131405 - Imidazoazepinone compounds: e

20090131406 - Cropwelllins and synthetic derivatives thereof used as medicaments: The present invention relates to cripowellins and synthetic derivatives thereof for treating diseases of man and also, in particular, to their use for preparing a medicament for treating cancer or other proliferative disorders in man and animal. Furthermore, the present invention relates to novel cripowellin derivatives and processes for their... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090131409 - 1,4,5,6,7,8-hexahydro -pyrrolo[2,3-d]azepines and -imidazo[4,5-d]azepines as modulators of nuclear receptor activity: and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF3, CF2H, S(O)nR6, and S(O)2N(R9)R10; Y is chosen from CR11 and N; Z is chosen from O and NH; R3 is chosen from —C(O)R12 and —C(O)N(R9)R10; and n, R1, R2 and R4-R12 are defined herein; compositions comprising one or... Agent: Wyeth/finnegan Henderson, LLP

20090131408 - Organic compounds: The present invention relates to novel aza-thia-benzoazulene derivatives of formula I as defined in the claims, their preparation, the use of these novel compounds for the preparation of pharmaceutical compositions, the use of these novel compounds and compositions for managing arthritis and arthritis-related conditions as well as in the treatment... Agent: Novartis Corporate Intellectual Property

20090131407 - Tetracyclic kinase inhibitors: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I): I wherein X, Y, Z, R1, R2, R3, Ra, Rb, and n are as described herein.... Agent: Genentech, Inc.

20090131410 - 3-azabicyclooctane derivatives as muscarinic receptor antagonists: Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors.... Agent: Ranbaxy Inc.

20090131411 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.... Agent: Foley & Lardner LLP

20090131412 - Novel 2-quinolone derivative: A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof which has a therapeutic or prophylactic effect on an SNS-related disease such as neuropathic pain. (1) wherein R1 and R2 independently represent an alkyl group having 1 to 4 carbon atoms or the like, or R1 and... Agent: Sughrue Mion, PLLC

20090131415 - Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor: Certain cycloalkyloxy- and heterocycloalkyloxypyridine compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20090131414 - Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c: Specifically substituted pyrido(3,2-d)pyrimidine derivatives having the structural formula (I) are useful for the treatment of hepatitis C.... Agent: Clark & Elbing LLP

20090131416 - Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor: Certain substituted pyrazinyl amide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20090131417 - Substituted pyridyl amide compounds as modulators of the histamine h3 receptor: Certain substituted pyridyl amide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20090131413 - Thienopyrazole derivative having pde7 inhibitory activity: r

20090131418 - Spiroazacyclic compounds as monoamine receptor modulators: The present invention relates to spiroazacyclic compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment... Agent: Knobbe Martens Olson & Bear LLP

20090131419 - Sulphones which modulate the action of gamma secretase: Disclosed are sulphones which modulate the action of gamma-secretase. The compounds are useful in the treatment or prevention of Alzheimer's disease.... Agent: Merck And Co., Inc

20090131420 - Novel heterocyclic analogs of biphenyl ethers: The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts and compositions. The present invention more particularly provides novel heterocyclic analogs of biphenyl ethers of the general formula (I).... Agent: Oliff & Berridge, PLC

20090131421 - Compounds for proteasome enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Ropes & Gray LLP

20090131422 - Salts of an ikk inhibitor: or solvates thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the Salts, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of the Salts, including crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological... Agent: Millennium Pharmaceuticals, Inc.

20090131424 - Thiazolyl-dihydro-chinazoline: wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as... Agent: Micheal P. Morris Boehringer Ingelheim Usa Corporation

20090131423 - Tyrosine kinase inhibitors: The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090131425 - Inhibitors of protein kinases: Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090131426 - Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-urea, compositions thereof, and uses therewith: Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.... Agent: Jones Day

20090131427 - Costunolide derivatives: Disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with a compound of the following formula:... Agent: Occhiuti Rohlicek & Tsao, LLP

20090131428 - Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer... Agent:

20090131429 - Pharmaceutical compounds: where A is a thiophene or furan ring and R1-R3 and n are defined in the specification. These compounds have activity as inhibitors of PI3K and may thus be used to treat diseased and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer,... Agent: Nixon & Vanderhye, PC

20090131431 - Pyrazolo[3,4-b]pyridine compounds, and their use as a pde4 inhibitors: e

20090131430 - Pyrido'2,3-dipyrimidines as anti-inflammatory agents: The present invention relates to novel azabicyclo derivatives as anti-inflammatory agents. The compounds provided herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as sepsis, rheumatoid arthritis, inflammatory bowel disease, type-1 diabetes, asthma, chronic obstructive pulmonary disorder, organ transplant rejection... Agent: Ranbaxy Inc.

20090131432 - Xanthine derivates, their preparation and their use in pharmaceutical compositions: e

20090131435 - Heterocyclic inhibitors of mek and methods of use: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, and X are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of... Agent: Hogan & Hartson LLP

20090131433 - Histamine-3 receptor antagonists: This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the... Agent: Pfizer Inc Steve T. Zelson

20090131434 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other... Agent: Paul D. Yasger Abbott Laboratories

20090131437 - Disubstituted ureas as kinase inhibitors: The invention relates to compounds of the formula (I), their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful... Agent: Novartis Corporate Intellectual Property

20090131436 - Pyrimidine derivatives: Novel pyrimidine derivatives of formula (I) to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.... Agent: Novartis Corporate Intellectual Property

20090131438 - Triazole derivative: A represents a sulfur atom, an oxygen atom, a formula —SO— or a formula —SO2—; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or the like; R2 represents an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 8... Agent: Sughrue Mion, PLLC

20090131440 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090131439 - Therapeutic agent for chronic obstructive pulmonary disease: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like;... Agent: Birch Stewart Kolasch & Birch

20090131441 - Metabolites of 2-arylpropionic acid derivatives and pharmaceutical compositions containing them: Metabolites of 2-(R)-4-isobutylarylpropionamides and pharmaceutical compositions containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these... Agent: Birch Stewart Kolasch & Birch

20090131442 - Method of treating bone pain caused by osteoarthritis: A method of treating bone pain caused by osteoarthritis by administering to a patient an effective amount of a composition containing a bone edema medication, such as a vasoactive medication or phosphodiesterase inhibitor, including a PDE-5 inhibitor.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090131443 - Method for prevention and/or treatment of rheumatoid arthritis: m

20090131444 - Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity: The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as... Agent: Astrazeneca R&d Boston

20090131445 - Furazano '3, 4-b! pyrazines and their use as anti-tumor agents: The present invention provides novel compounds of the formula (I) and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090131446 - Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases: e

20090131448 - 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors:

20090131447 - Combination therapy: This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain.... Agent: Osha Liang L.L.P.

20090131449 - Use of trpv1 receptor antagonists for treating dry eye and ocular pain: Methods of treating symptoms of dry eye by administering inhibitors of transient receptor potential cation channel, subfamily V, member 1 (TRPV1) are disclosed. Methods of preventing or alleviating ocular pain by administering TRPV1 inhibitors are also disclosed.... Agent: Alcon

20090131450 - Use of pkc inhibitors in diabetic complications: The present invention pertains to the use of a PKC inhibitor in the manufacture of a medicament in the treatment or prevention of diabetic complications.... Agent: Novartis Corporate Intellectual Property

20090131451 - Diagnosis and treatment of type 2 diabetes and other disorders: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.... Agent: Merck And Co., Inc

20090131452 - Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor: e

20090131453 - Benzylpiperazine derivatives as motilin receptor antagonists:

20090131454 - New compounds 067: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090131456 - Caspase inhibitors and uses thereof: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated... Agent: Michael C. Badia Vertex Pharmaceutical Incorporated

20090131455 - Heterocyclic derivatives: wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090131457 - Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.... Agent: Novartis Corporate Intellectual Property

20090131458 - Compounds: The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090131459 - 2-thioxanthine derivatives acting as mpo-inhibitors: The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1-C6 alkoxy; and at least one of said C1-C6 alkyl or said C1-C6 alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090131460 - Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof: The present invention relates to the use of pyrido[2,3-d]pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to pyrido-[2,3-d]pyrimidines compounds per se and their use as medicines. The present invention also concerns... Agent: Philip S. Johnson Johnson & Johnson

20090131461 - Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity: Compounds of formula (IA) or (IB), are inhibitors of aurora kinase activity: Formula (IA), (IB) wherein -L1Y1-[CH2]z- is a linker radical wherein Y1, L1 and z are as defined in the claims; R6 is C1-C4alkoxy, hydrogen or halo; W represents a bond, —CH2—, —O—, —S—, —S(═O)2—, or NR5— where R5... Agent: Banner & Witcoff, Ltd.

20090131462 - Fungicidally active agent: The invention relates to a fungicidally active agent containing at least one other defined fungicide in addition to the fungicide N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluormethyl)-1H-pyrazol-4-carboxamide (penthiopyrad). The invention also relates to a method for controlling pathogenic fungi using one such agent, and to the use of said agent for controlling pathogenic fungi.... Agent: Birch Stewart Kolasch & Birch

20090131463 - Novel compounds: e

20090131464 - Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors: The invention relates to a compound of a formula (I): or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders.... Agent: Merck And Co., Inc

20090131465 - Synthesis and crystalline forms of melanocortin-4 receptor agonist: The present invention relates to a process for producing crystalline N-[1-((3R)-1′-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-6-chloro-5-methyl-2,3-dihydrospiro[indene-1,4′-piperidine]-3-yl)-1-methylethyl]acetamide, and novel salts, solvates, hydrates and polymorphs thereof.... Agent: Merck And Co., Inc

20090131466 - Pharmaceutical compositions: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from... Agent: Alfred Liang

20090131467 - Heterocycle compound, and production process and application thereof: The compound of the present invention is a novel compound which has a specific heterocycle skeleton, particularly a pyrazolonaphthyridine or pyrazoloquinoline skeleton having an organic group (e.g., a carbocycle and a heterocycle) bonding through an alkylene group at 3-position and a carbocycle bonding at 5-position and has a phosphodiesterase IV... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090131468 - Bis-(sulfonylamino) derivatives in therapy 065: e

20090131471 - Compositions useful for treating gastroesophageal reflux disease: The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090131469 - Pharmaceutical agent comprising solifenacin: There is provided an agent comprising solifenacin succinate in an amount of 5 mg to 10 mg or solifenacin or a pharmaceutically acceptable salt thereof in an amount equimolar to 5 mg to 10 mg of solifenacin succinate for improvement of urinary urgency, pollakiuria and urinary incontinence due to neurogenic... Agent: Sughrue-265550

20090131470 - Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders: Compounds of formula (I) are inhibitors of PDK1 and CHK1 activity, and of use in the treatment of cancer and autoimmune disorders (I): wherein R2 is a radical of formula R7—(CH2)n−, or a radical of formula -Alk-N(—R5)—R9 wherein n is 0, 1, 2 or 3 and Alk is C1-C6 alkylene;... Agent: Banner & Witcoff, Ltd.

20090131472 - P38 kinase inhibiting agents: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin... Agent: Merck And Co., Inc

20090131473 - 2-(aryloxy) acetamide factor viia inhibitors useful as anticoagulants: m

20090131474 - Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby: The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase, also known as Protein Kinase B, an enzyme that is believed to play a key role in the inhibition of apoptosis and thus in the etiology of cancer and... Agent: Catalyst Law Group, Apc

20090131475 - Compositions and methods for the treatment of metabolic disorders: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B—C tripartite structure, wherein A, B, and C are identical... Agent: Fulbright & Jaworski, LLP

20090131476 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131477 - New use of iloperidone: The invention relates to the use of iloperidone in the treatment of affective disorders, including bipolar mood disorders.... Agent: Novartis Corporate Intellectual Property

20090131478 - Growth hormone secretagogues: A family of peptides and peptidomimetic compounds useful as GHS analogs according to either formula (I) or (II) as depicted below: or a pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification.... Agent: Alan F. Feeney Biomeasure

20090131479 - Small-volume oral transmucosal dosage: Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090131480 - Dihydropyridine compounds for neurodegenerative diseases and dementia: The invention provides methods for treating and/or preventing cognitive impairments, dementia, or neurodegenerative diseases and disorders (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis) in patients by administering therapeutically effective amounts of an AMPA receptor antagonist (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts of nootropics (e.g., cholinesterase inhibitors)... Agent: Venable LLP

20090131482 - Methyl-benzimidazole derivatives: e

20090131481 - Transcription factor modulating compounds and methods of use thereof: Substituted benzimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of using substituted benzimidazole compounds, in, e.g., reducing virulence and infectivity, inhibiting biofilms and treating bacterial infections are also provided.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090131483 - 2-pyridine derivatives as inhibitors of neutrophile elastase: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and X are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds... Agent: Morgan Lewis & Bockius LLP

20090131484 - Preventive or remedy for bowel disease: [Means for Solution] It was found for the first time that CRAC/SOC channels play a physiologically important role in water secretion or absorption in gastrointestinal epithelia cells and a CRAC/SOC channel inhibitor is useful for preventing and treating diarrhea caused by various factors, and a preventive and a remedy for... Agent: Sughrue-265550

20090131485 - Deuterated pirfenidone: This invention relates to novel substituted pyridinones, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090131486 - 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial: wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil... Agent: Morgan Lewis & Bockius LLP

20090131487 - Growth factor-binding compounds and methods of use: Growth factor binding compounds having a plurality of acyclic isophthalic acid groups attached to a non-peptide organic scaffold and pharmaceutical compositions of the same are disclosed. Methods of administering and using the growth factor binding compounds or the growth factor binding compositions are also taught. These novel growth factor binding... Agent: Dickstein Shapiro LLP

20090131488 - Compositions and methods for treating hyperproliferative epidermal diseases: The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration where the compositions contain nicotinamide and a vitamin D metabolite, calcipotriol, which are particularly effective in treating and in the maintenance treatment of psoriasis... Agent: Winston & Strawn LLP Patent Department

20090131489 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent: Philip S. Johnson Johnson & Johnson

20090131490 - Methods of treating pulmonary disease using acetazolamide and structurally related derivatives: wherein R1, R2 or R3 are each independently a C1 to C6 alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome,... Agent: Nixon Peabody LLP - Patent Group

20090131491 - Isoxazole derivative and isothiazole derivative having inhibitory activity on 11(beta)-hydroxysteroid dehydrogenase type i: e

20090131492 - Indole derivatives as cftr modulators: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20090131493 - Substituted benzimidazoles for treatment of histomoniasis: The present invention relates to the use of substituted benzimidazoles for controlling histomoniasis, especially in turkeys.... Agent: Bayer Healthcare LLC

20090131495 - Method for the prevention and treatment of essential tremor by regulating alpha1g t-type calcium channel or by t-type calcium channel blockers: The present invention relates to a method for the prevention and treatment of essential tremor by blocking α1G T-type calcium channel, a preventive and therapeutic agent for essential tremor containing the α1G T-type calcium channel blocker as an active ingredient, and a screening method of a preventive and therapeutic agent... Agent: Klarquist Sparkman, LLP

20090131494 - Non-nucleoside reverse transcriptase inhibitors: Certain 1H-indole-2-carboxylates and -2-carboxamides are HIV reverse transcriptase inhibitors. These indole compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their... Agent: Merck And Co., Inc

20090131496 - Pyrazolone derivative emulsion formulations: Pyrazolone derivative emulsion formulations are provided. The emulsion formulations include a pyrazolone derivative active agent, e.g., Edaravone, oil, water and an emulsifier. Also provided are methods of making and using the subject emulsion formulations.... Agent: Bozicevic, Field & Francis LLP

20090131497 - Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments: The present invention relates to indoline-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff, Ltd.

20090131498 - Enantioselective synthesis of merrilactone and its analogs: This invention provides a method of synthesizing enantioenriched merrilactone A and enantiopure merrilactone A, as well as an improved method of synthesizing racemic merrilactone. This invention also provides intermediate compounds and methods of treating peripheral neuropathies... Agent: Cooper & Dunham, LLP

20090131499 - Photodynamic therapy for skin related problems: PhotoDynamic Therapy method is used to treat problems associated with pilosebaceous units including acne and other skin conditions. At least one liposomal-formulated, hydrophobic photosensitizer, such as a dihydro- or tetrahydro-porphyrin, is topically applied to acne affected regions, and is allowed to penetrate the hair follicle before being irradiated with a... Agent: Dr. Bolesh J. Skutnik Ceramoptec Industries, Inc.

20090131500 - Porphyrin derivates and their use as photosensitizers in photodynamic therapy: The present invention relates to novel porphyrin derivates of formula (I), especially to porphyrins which carry substituted phenyl moieties in meso-position. The porphyrin derivates of the invention are useful as photosensitizers in photodynamic therapy (PDT), especially in photodynamic tumor therapy. Due to their excellent photophysical properties the compounds of formula... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090131501 - Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof: The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090131503 - 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity: The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.... Agent: Clark & Elbing LLP

20090131502 - Biologically active compounds: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic... Agent: Edwards Angell Palmer & Dodge LLP

20090131505 - 7-amido-isoindolyl compounds and their pharmaceutical uses: The invention encompasses 7-amido-isoindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.... Agent: Jones Day

20090131504 - Use of melatonin-containing oral supplement with animals: The diet of a healthy non-human animal is supplemented with a melatonin-containing supplement by providing a dietary supplement containing melatonin in an amount from about 0.1 mg to about 12 mg/kg of body weight of the animal and administering the dietary supplement to the animal at a regular interval. The... Agent: Standley Law Group LLP

20090131507 - N-arylsulfonyl-3-aminoalkoxyindoles: N-arylsulfonyl-3-aminoalkoxyindoles indole compounds, radioisotopes, stereoisomers, geometric forms, N-oxides, polymorphs and pharmaceutically acceptable salts.... Agent: Iphorgan, Ltd.

20090131506 - Oxindoles as kinase inhibitors: The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition.... Agent: Millen, White, Zelano & Branigan, P.C.

20090131508 - Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug: The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090131509 - Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase n inhibitors: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—COONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5... Agent: Harness, Dickey & Pierce, P.L.C

20090131510 - Compounds with activity at estrogen receptors: e

20090131511 - Palmarumycin based inhibitors of thioredoxin and methods of using same: Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer.... Agent: Pepper Hamilton LLP

20090131512 - Inhibition of type i in ifn production: The invention provides methods for decreasing type I IFN production by human plasmacytoid dendritic cells in response to TLR activation.... Agent: Robins & Pasternak

20090131513 - Anti-inflammatory modalities: Anti-inflammatory modalities are described with reference to select isoflavonoid compounds, compositions containing same and the use of said compounds and/or compositions in treatment, particularly for the treatment of inflammatory diseases and related conditions.... Agent: Sughrue Mion, PLLC

20090131514 - Buccal, polar and non-polar sprays containing propofol: Buccal aerosol sprays using polar and/or non-polar solvents have now been developed which provide propofol for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: propofol, a polar solvent and an optional flavoring agent; formulation II: propofol,... Agent: Dickstein Shapiro LLP

20090131515 - Combination of antidiabetic drugs: The combination of R-4-trimethylammonio-3-(tetra-decylcarbamoyl)-aminobutyrate and metformin is disclosed. Said combination of anti-diabetic drugs exerts a synergic action and allows the administration of the two drugs at doses such as to avoid or reduce the occurrence of side effects. The combination is also useful for improving the therapeutic cover far from... Agent: Nixon & Vanderhye, PC

20090131516 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131517 - Antimicrobial and antifungal powders made by flame spray pyrolysis: A flame spray pyrolysis method for producing a doped silica(SiO2) having antimicrobial and/or antibacterial and/or antifungal effect and being in the form of particles is disclosed. Said flame made doped silica comprises at least one functional dopant consisting of at least one antimicrobial and/or antibacterial and/or antifungal acting metal and/or... Agent: Richard F. Jaworski C/o Cooper & Dunham

20090131518 - Insecticidal and miticidal mixtures of bifenthrin and cyano-pyrethroids: The present invention is directed to novel insecticidal and/or miticidal compositions comprising bifenthrin and a cyano-pyrethroid. The compositions exhibit an unexpected increase in insecticidal activity as compared to the insecticidal activity of the individual components.... Agent: Patent Administrator Fmc Corporation

20090131519 - Use of growth regulators for reducing or preventing the contamination of plants and vegetable products by trichothecene-producing mould toxins: The present invention relates to the use of growth regulators selected from acylcyclohexanedione derivatives and quaternary ammonium compounds for reducing or preventing the contamination of plants and plant products with mycotoxins formed by trichothecene-producing fungi.... Agent: Birch Stewart Kolasch & Birch

20090131520 - Lipid metabolism improving composition: Disclosed is a composition for improving lipid metabolism. The composition for improving lipid metabolism comprises a fatty acid menthol ester as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090131521 - Aqueous retinoid and benzoyl peroxide gel: Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid.... Agent: Reed Smith LLP

20090131523 - Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis: Lipid compositions are provided for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carcinogenesis.... Agent: The Nath Law Group

20090131522 - Skin cell activator extracted from liver of fish or shellfish and hair growth agent using the same: Disclosed are a skin cell activator extracted from a pufferfish liver, and a hair growth agent comprising 10 volume % or more of the skin cell activator. The skin cell activator comprises an organic substance which contains an alcohol- and other organic solvent-soluble fat/oil component extracted from a pufferfish liver,... Agent: Jordan And Hamburg LLP

20090131524 - Sialic acid abc transporters in prokaryotes therapeutic targets: This invention provides a novel bacterial sialic acid transporter that is a member of the family of ABC transporters. The transporter is a useful target for pharmaceuticals.... Agent: Weaver Austin Villeneuve & Sampson LLP

20090131525 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131526 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131527 - Novel anthranilic acid derivatives and chloride channel blocking agent containing the same: The present invention relates to novel anthranilic acid derivatives represented by Chemical Formula I, and a chloride channel blocking agent containing the anthranilic acid derivative or its pharmacologically acceptable salts as an active ingredient. In another aspect, the present invention relates to a method of accurately and efficiently detecting the... Agent: LexyoumeIPGroup, LLC

20090131528 - Salt: The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt.... Agent: Novartis Corporate Intellectual Property

20090131530 - 4- (or 5-) substituted catechol derivatives: e

20090131529 - Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents: In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering... Agent: Wilson Sonsini Goodrich & Rosati

20090131531 - Amide compounds and their use:

20090131532 - Method of preemptive treatment of inflammation, algesia and poor healing using topical capsaicin: A method of treating the conditions which involve inflammation, algesia and ineffective healing by preemptively applying capsaicin topically prior to or at the onset of the process thereby diminishing harmful effects.... Agent: Ryan Kromholz & Manion, S.c.

20090131533 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131534 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090131535 - Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors: e

20090131536 - Treating or preventing renal cancer using a dimethane sulfonate: The present invention features methods of treating renal cancer by administration of certain dimethylsulfonate compounds. The present invention further features administration protocols and dosing schedules for methods of treating patients suffering from renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.... Agent: Edwards Angell Palmer & Dodge LLP

20090131537 - Wound healing compositions: Formulations and methods for treating wounds utilizing these formulations are disclosed. The formulations accelerate wound healing by providing a unique serum-free cellular nutrient medium that supports wound healing of mammalian skin in the absence of protein growth factors. The protein-free composition contains physiological levels of a retinoid compound. This retinoid-containing... Agent: Milde & Hoffberg, LLP

20090131539 - Mixture: A mixture of substances, in particular a biocide for combating human and animal parasites comprising a) an A component containing at least one type of alcohol of general formula R1-OH or R1-OH—R1′, wherein R1 and/or R1′ is an alkyl radical associated with a hydroxyl group which comprises from 1 to... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20090131538 - Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate: Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of a pharmaceutically acceptable salt of formaldehyde sulfoxylate sufficient to prevent significant growth of microorganisms for at least 24 hours after adventitious contamination.... Agent: Venable LLP

20090131540 - Biodegradable magnesium based metallic material for medical use: A biodegradable magnesium based metallic material for medical use which is degraded and absorbed in vivo, characterized by comprising a film, which contains magnesium oxide and magnesium hydroxide and is formed on the surface of crystallized magnesium or a magnesium alloy by anodic oxidation. This magnesium based metallic material is... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090131542 - Emulsifier combination, emulsion containing the emulsifier combination, and a process for its production: An emulsifier concentrate containing: (a) a C8-14 alkyl oligoglycoside, (b) a polyol hydroxystearate; (c) a C6-22 acyl glutamate; (d) water; and (e) optionally, at least one auxiliary component, and wherein the composition is ethoxylate-free.... Agent: Fox Rothschild LLP

20090131541 - Gelatin-containing topical composition: This invention provides a topical pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically active agent and a gelling agent, characterized in that said gelling agent comprises a fish gelatin and a polysaccharide.... Agent: Knobbe Martens Olson & Bear LLP

  
05/14/2009 > patent applications in patent subcategories. archived by USPTO category

20090124536 - Calcium phosphate/sulfate-based bone implant composition: A bone implant composition, the composition comprising calcium sulphate and slowly soluble source of calcium, orthophosphate and hydroxyl ions. The composition may be provided in powder or granulated form.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090124534 - Trehalose click polymers for delivery of biologically active molecules: Novel trehalose click polymers have in vitro and in vivo application in the cellular delivery of biologically active molecules, including nucleic acids and polypeptides. The trehalose click polymers of the present invention provide increased stability in serum as compared with other non-viral vectors, and are particularly useful in protecting nucleic... Agent: Dinsmore & Shohl, LLP

20090124535 - Viscous terpolymers as drug delivery platform: Disclosed are terpolymer compositions of lactide, glycolide, and caprolactone and methods of making such polymers with an initiator. Methods of using the terpolymers as a drug delivery platform are also disclosed.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090124537 - Screening method for bone morphogenetic mimetics: Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions... Agent: Edwards Angell Palmer & Dodge LLP

20090124539 - Methods of treating infection: The present invention relates to methods of inhibiting the proliferation of bacteria for either ex vivo or in vivo use. The invention also relates to methods of treating a patient infected with an antibiotic resistant bacteria by administering a pharmaceutical composition comprising an Empedopeptin; methods of sanitizing surfaces and instruments;... Agent: Honigman Miller Schwartz & Cohn LLP

20090124538 - Selective r-cadherin antagonists and methods: An isolated peptide useful as a selective antagonist of mammalian R-cadherin comprises 3 to 30 amino acid residues, three contiguous residues of the peptide having the amino acid sequence Ile-Xaa-Ser; wherein Xaa is an amino acid residue selected from the group consisting of Asp, Asn, Glu, and Gln. Preferably Xaa... Agent: Olson & Cepuritis, Ltd.

20090124543 - Activity dependent neurotrophic factor iii (adnf iii): The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and... Agent: Townsend And Townsend And Crew, LLP

20090124540 - Anti-adhesion composites and methods of use thereof: Described herein are composites that inhibit or reduce adhesion between two or more tissues. Also described herein are methods of using the composites.... Agent: King & Spalding LLP

20090124546 - Antimicrobially active peptides: An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.... Agent: Knobbe Martens Olson & Bear LLP

20090124544 - Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants: The present invention relates to protease resistant mutants of human growth hormone, which contain newly introduced proteolysis resistant mutations and N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the naturally occurring human growth hormone. The polynucleotide coding sequences for... Agent: Morgan, Lewis & Bockius LLP (sf)

20090124547 - Compounds for intracellular delivery of therapeutic moieties to nerve cells: e

20090124541 - Method for the recovery and application of novel human defensins as biologically active proteins for the treatment of infections and other diseases: The invention relates to the novel peptides, derived from human blood, hBD-5 (human beta-defensin-5), hBD-6, hBD-7, hBD-8, hBD-10, hBD-11, hBD-12, hBD-13, hBD-14, hBD-15, hBD-16, hBD-17, hBD-18, hBD-19, hBD-20, hBD-22, hBD-23, hBD-24, hBD-25, hBD-26, hBD-27, hBD-28, hBD-29, hBD-30, hBD-31 and hBD-32 and their derivatives whose structure was elucidated for the purpose... Agent: Jacobson Holman PLLC

20090124548 - Method of using fish plasma components to inhibit glial scarring and promote functional recovery in the mammalian cns: A method includes applying salmon fibrin at a central nervous system injury site. For example, applying salmon fibrin can include injecting salmon fibrin. The method can also include causing the suppression of astrocyte activation, whereby glial scarring is at least reduced. The functional recovery of a patient who has suffered... Agent: Ip Strategies

20090124552 - Methods and compositions for regenerating connective tissue: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well... Agent: Alston & Bird LLP

20090124542 - Methods and reagents for treatment and diagnosis of age-related macular degeneration: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.... Agent: Townsend And Townsend And Crew, LLP

20090124549 - Methods for producing an immune response to tuberculosis: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of... Agent: Klarquist Sparkman, LLP

20090124551 - Methods of administering bone health compositions derived from milk: The invention relates to bone health compositions comprising an acidic protein fraction of milk, to a method of producing said bone health composition, to methods of treatment comprising said bone health compositions and to medicinal uses of said bone health compositions. One broad aspect of the invention provides a bone... Agent: Knobbe Martens Olson & Bear LLP

20090124545 - Novel nucleic acid encoding a novel protein of candida albicans and uses thereof: A novel Candida albicans nucleotide and polypeptide, CaSRF1, involved in regulating the morphogenetic transformation and virulence in response to engulfment by the immune response cells of its model host is described. The gene is unique in its ability to affect the virulence-associated morphogenesis in vivo but is not required for... Agent: Intellectual Property Dept. Dewitt Ross & Stevens Sc

20090124550 - Thrombin peptide derivative dimers: Disclosed are thrombin peptide derivative dimers comprising two polypeptides having the amino acid sequence Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:2), or a C-terminal truncated fragment of the polypeptide having at least six amino acids. Zero, one, two, or three amino acids in the polypeptide or polypeptide fragment differ from the corresponding position... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090124554 - Buccal, polar and non-polar spray or capsule containing drugs for treating pain: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent: Dickstein Shapiro LLP

20090124553 - Suppression of inflammation associated with transplantation using an epsilon pkc inhibitor: The described compositions and methods relate to the suppression of inflammatory responses following allograft transplantation by administering an inhibitor of epsilon protein kinases c (εPKC) following transplantation.... Agent: King & Spalding LLP

20090124555 - Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents: The invention relates to the use of Histogranin-like compounds to reduce P2X7 (also designed P2Z) receptor function. The invention also provides a method for the prevention and treatment of rheumatoid arthritis and a variety of diseases/disorders including inflammatory disorders and neurodegenerative diseases.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090124556 - Peptides exhibiting efficacies of improvement in skin conditions or treatment of periodental diseases: The present invention relates to a composition for improving a skin condition or treating a periodontal disease, which comprises as an active ingredient a basic fibroblast growth factor-derived peptide. The peptides of this invention exhibit superior efficacies and much better stability and skin permeation than natural-occurring bFGF. In these connections,... Agent: The Nath Law Group

20090124557 - Compositions and methods for treating cancer: A composition which comprises a chimeric polypeptide is provided. The chimeric polypeptide having a flagellin amino acid sequence and a mucin 1 amino acid sequence which includes at least a 7 amino acid sequence of the mucin 1 tandem repeat which can be used to elicit an immune response against... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090124558 - Compositions and methods for treating neural anoxia and spreading depression: Compositions and methods for protecting neural tissue (e.g., neurons) from anoxia and spreading depression (SD) involve inhibiting the cGMP-dependent protein kinase (PKG) pathway. It was discovered that the PKG pathway plays a crucial role in regulating SD and tolerance to anoxia in the central nervous system (CNS). Inhibition of the... Agent: Akerman Senterfitt

20090124559 - Soft protease inhibitors and pro-soft forms thereof: The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090124560 - Composition containing peptide as active ingredient: The invention provides a composition used for promoting glucose uptake, which comprises a peptide having an effect of promoting glucose uptake as the active ingredient, as well as a composition comprising a dipeptide containing leucine and/or isoleucine as the active ingredient. The composition is effective in preventing or treating diabetes... Agent: The Nath Law Group

20090124561 - Dihydroxyphenyl compounds and glucoside compounds thereof: e

20090124562 - Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent: The present invention provides the compounds represented by the general formula of “Formula 1” or the salt thereof. The compounds are compounds having an organic group introduced on a particular ketone group of VST that functions to inhibit induction of GRP 78 expression, similarly to VST, and is applicable, for... Agent: Jordan And Hamburg LLP

20090124563 - Oral extended-release composition: The invention is directed to controlled release formulations containing drugs which are preferably considered sparingly soluble to insoluble and which are suitable for administration to a patient in need of treatment related thereto, and methods of manufacturing the same.... Agent: Hedman & Costigan P.C.

20090124565 - Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc: Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions.... Agent: Young & Thompson

20090124564 - Compositions and methods for regulating apoptosis: Methods and pharmaceutical compositions for regulating apoptosis and treating pathologies associated with disregulated apoptosis are provided. Specifically the present invention provides agents capable of modulating the expression of an MCD-containing protein (e.g., Mtch2) capable of tBID binding activity and/or the tBID binding activity of the MCD-containing protein.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090124567 - Influenza therapeutic: The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for... Agent: Choate, Hall & Stewart LLP

20090124569 - Inhibition and treatment of prostate cancer metastasis: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.... Agent: Casimir Jones, S.c.

20090124571 - Method for the synthesis of oligonucleotide derivatives: e

20090124570 - Methods and compositions for facilitating tissue repair and diagnosing, preventing, and treating fibrosis: Compositions and methods for facilitating tissue repair by enhancing the actions of BIGH3 or at least one of its downstream effector molecules in injured tissue, and for the diagnosis, prophylactic and therapeutic treatment of fibrosis by inhibiting the actions of BIGH3 or at least one of its downstream effector molecules,... Agent: Edell Shapiro & Finnan , LLC

20090124566 - Methods and compositions for the treatment of erythrocyte diseases: Methods to determine the susceptibility of a subject to erythrocyte diseases are provided. The methods comprise determining the miRNA compositions of erythrocytes from the subject. The present invention has discovered that erythrocytes comprise microRNA (miRNA) populations and the populations can be profiled or analyzed and used to determine the susceptibility... Agent: Alston & Bird LLP

20090124568 - Use of stem cells to generate inner ear cells: This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear.... Agent: Fish & Richardson PC

20090124572 - Iron-containing nutritional supplement: The present invention relates to a nutritional supplement, and particularly, to an oral nutritional supplement which contains an iron fortificant comprising a ferric pyrophosphate chelate. The nutritional supplement can also include vitamins, non-ferrous minerals, and other ingredients. The nutritional supplement is useful for providing iron to animals, and is intended... Agent: Kent Barta S.c.

20090124573 - Immunomodulating compounds and related compositions and methods: Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.... Agent: Steinfl & Bruno

20090124574 - Carotenoid analogs and derivatives for the prevention of platelet aggregation: The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090124575 - Method of inhibition the growth of algae: To inhibit the growth of algae, glucosamine is added into water needed to be treated.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090124576 - Triazine derivatives:

20090124577 - Intermediate compounds for the preparation of an angiotensin ii receptor antagonist: It comprises new substituted 4-valinylmethylphenyl boronic acids of formula (II) and their derivatives and also its preparation process. It also comprises a preparation process of Valsartan (I) from such intermediates. The process comprises the reaction of the new 4-valinylmethylphenyl boronic compounds with a (halophenyl)tetrazole compound which proceeds with high yields.... Agent: Berenbaum, Weinshienk & Eason, P.c

20090124578 - Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090124579 - Systems and methods for determination of compounds for stimulation or inhibition of neocalcification: Disclosed are systems and methods as may be used for development of compounds that can be utilized for prevention of pathological calcification. Disclosed are functional models can represent in great detail the first steps in protein-membrane interaction leading to calcification. Disclosed compounds include those that interfere with pathologic calcification processes... Agent: Dority & Manning, P.A.

20090124580 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.... Agent: Rigel Pharmaceuticals Inc.

20090124581 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090124582 - Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use: Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090124583 - 7-n-substituted phenyl tetracycline compounds: 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090124584 - Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen: Methods and formulations for the regeneration of vaginal tissue and vaginal cell health resulting from vaginal cell hypoxia in a human female. A pharmaceutical composition for topical non-systemic administration is formulated containing a hormonal agent administered to the vagina, vulvar area of the individual undergoing treatment.... Agent: Dilworth & Barrese, LLP

20090124585 - Novel crystalline pharmaceutical product: t

20090124586 - Aqueous-based pharmaceutical composition: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the... Agent: Fox Rothschild LLP Sanofi-aventis

20090124587 - Methods for treating cancer using 17alpha-hydroxylase/c17,20-lyase inhibitors: Methods for treating certain cancers in patients, such as mammals, using certain 17α-hydroxylase/C17,20-lyase inhibitors are discussed herein. More particularly, methods for treating cancers comprising administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e. 3β-acetoxy-17-(3-pyridyl) androsta-5,16-diene) and metabolites thereof are described. In addition, methods for treating cancers that are refractory to... Agent: Jones Day

20090124588 - Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions: and physiologically acceptable solvates thereof, physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090124589 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090124590 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090124591 - Synthesis and use of cationic steroids for anti-inflammatory drug therapy: The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090124593 - Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications: Compositions having an effective amount of an antibacterial agent may be useful in the treatment of amyotrophic lateral sclerosis (ALS). The compositions may include an extraordinary amount of the antibacterial agent.... Agent: Haugen Law Firm Pllp

20090124594 - Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases: Provided is a method of treating the health-related quality-of-life (HRQOL) symptoms of a lung disease, comprising the administration of an inhalable aerosole of aztreonam lysine. The method is suitable for the short term and sustainable long term treatment of HRQOL symptoms.... Agent: Gilead Sciences Inc

20090124595 - Mapk/erk kinase inhibitors: o

20090124592 - Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity: This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090124596 - Chemical compounds 637: i

20090124597 - Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors: Described herein are compounds that have a spiro structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds,... Agent: Genomics Institute Of The Novartis Research Foundation

20090124598 - Pharmaceutical use of substituted amides: The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture... Agent: Transtech Pharma, Inc.

20090124599 - Fungicidal mixtures: e

20090124600 - N-alkyl-azacycloalkyl nmda/nr2b antagonists: Compounds represented by Formula (I): and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke.... Agent: Merck And Co., Inc

20090124603 - Diazepan orexin receptor antagonists: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20090124602 - Kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20090124601 - Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor: Tartaric acid salts of (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]hexahydro-3-(2,2,2-trifluoroethyl)-2H-1,4-diazepin-2-one are potent inhibitors of dipeptidyl peptidase-IV and are useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as Type 2 diabetes. The invention also relates to crystalline anhydrate forms of the tartaric acid salts as well as a process... Agent: Merck And Co., Inc

20090124604 - 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases: The invention concerns a compound of the Formula (I) wherein m is 1-2 and each R1 is a group such as cyano, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is trifluoromethyl or (1-6C)alkyl; R3 is hydrogen or halogeno; and R4 is isoxazolyl; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical... Agent: Morgan Lewis & Bockius LLP

20090124605 - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity,... Agent: Scully Scott Murphy & Presser, PC

20090124606 - Composition for treatment of psychosis: New pharmaceutical combination providing to decrease or eliminate the extrapyramidal side effects of antipsychotic active ingredients by combination of deramciclane with a classic antipsychotic agent (e.g. haloperidol, chloroprozamine or levoprozamin) or an atypical antipsychotic agent (e.g. risperidone, iloperidone or olanzapine).... Agent: K.f. Ross P.C.

20090124607 - Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases: Compounds of formula (I): or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).... Agent: Fish & Richardson P.C.

20090124608 - Cb2 receptor modulators in neurodegenerative diseases and applications of the same: Compositions for the treatment of neurodegenerative diseases are disclosed. Methods of treating and monitoring progression of a neurodegenerative disease are disclosed. According to the present invention, a selective CB2 receptor modulator may be administered to a mammal for the treatment of a neurodegenerative disease.... Agent: Cyr & Associates, P.A.

20090124609 - Fused heterocyclic derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20090124610 - Pharmaceutical compounds: Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof, wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; R1a is an optionally substituted aryl or heteroaryl group; R1b is hydrogen... Agent: Heslin Rothenberg Farley & Mesiti PC

20090124611 - Pyrazolopyridine-1,4-diamines and analogs thereof: Pyrazolopyridine-1,4-diamines and analogs thereof, e.g., pyrazolo[3,4-c]pyridine-1,4-diamines, pyrazolo[3,4-c]quinoline-1,4-diamines, 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinoline-1,4-diamines, and pyrazolo[3,4-c]naphthyridine-1,4-di-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090124612 - Fused heterocyclic derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20090124613 - Substituted heterocyclic ethers and their use in cns disorders: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090124614 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders: wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse,... Agent: Philip S. Johnson Johnson & Johnson

20090124615 - Benzimidazole thiophene compounds: The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090124616 - 7-nonsubstituted indole mcl-1 inhibitors: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090124617 - Quinolone derivative or salt thereof: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.... Agent: Sughrue-265550

20090124618 - 2-morpholino-4-pyrimidone compound: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R′ represents a C1-C6 alkyl or the like; q represents 0 or an integer... Agent: Greenblum & Bernstein, P.L.C

20090124619 - Novel compounds: c

20090124620 - Plasminogen activator inhibitor-1 inhibitor:

20090124621 - Pyrazole derivatives as kinase inhibitors:

20090124622 - Medicament containing a thiazole derivative as an active ingredient: A prophylactic and/or therapeutic agent for sinusitis, nasal obstruction•nasal mucosa congestion containing N-{2-[2-[(3-fluorophenyl)imino]-4-(4-morpholin-4-ylphenyl)-1,3-thiazol-3(2H)-yl]ethyl}-N′-methylurea represented by the formula (1) or its pharmaceutically acceptable salt as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090124623 - Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors: The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in... Agent: Dykema Gossett PLLC

20090124624 - Substituted 1-aminophthalazine derivatives, preparation thereof and therapeutic application thereof: e

20090124628 - 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments:

20090124627 - Compositions for sleeping disorders: Provided herein is a method for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder using a composition that contains an effective amount of one or more compounds.... Agent: Squire, Sanders & Dempsey L.L.P.

20090124625 - Novel alkynyl derivatives as modulators of metatropic glutamate receptors: The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5... Agent: Edwards Angell Palmer & Dodge LLP

20090124626 - Pharmaceutical agent comprising insulin resistance improving agent: To provide a method for treating diabetes which has an excellent hypoglycemic action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor and an insulin sensitizer in combination.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090124629 - 3-(1,2,4-triazol-3ylalkyl) azabriclo (3.1.0) hexane derivatives as modulators of dopamine d3 receptors:

20090124630 - 3, 4-dihydro-2-naphthamide derivatives as selective dopamine d3 ligands: The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.... Agent: Stites & Harbison PLLC

20090124631 - Combination therapy: The invention relates to the treatment of mammalian diseases manifested by abnormal cell growth and/or abnormal cell proliferation. More particularly, the invention relates to the use of combination therapies to control abnormal cell growth and/or abnormal cell proliferation. In particular, the invention relates to the use of isotype-selective inhibitors of... Agent: Keown & Zucchero, LLP

20090124632 - Methods and kits related to the topical administration of quinolone antibiotics°: The present invention is generally directed to the treatment of dermatological bacterial infections, burns and wounds. It is more specifically directed to the treatment of such infections, burns and wounds using one or more quinolone antibiotics. In one method of treatment aspect, an aqueous solution containing Ciprofloxacin-HCl is topically applied... Agent: 212&#xb0 Consulting, Inc. Bungalow B

20090124633 - N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases: The present invention relates to heterocyclic substituted N-Oxides of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical... Agent: Millen, White, Zelano & Branigan, P.C.

20090124634 - Novel dipodazine compounds and applications: The invention relates to a novel class of dipodazine derivatives, suitable for use as surface on-growth inhibiting agents.... Agent: Dinsmore & Shohl, LLP

20090124635 - Chemical compounds: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, m and n are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of... Agent: Pfizer Inc Steve T. Zelson

20090124636 - Chemical compounds: The present invention provides compounds of formula (I) wherein R1 to R6 and m are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases,... Agent: Pfizer Inc Steve T. Zelson

20090124637 - Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives 794: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090124638 - Anti-inflammatory pyrazolopyrimidines: The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition.... Agent: Townsend And Townsend And Crew, LLP

20090124639 - valacyclovir formulations: The present invention relates to valacyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.... Agent: Emisphere Technologies, Inc

20090124640 - Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor: The present invention relates to a new compound A: [Chemical formula should be inserted here. Please see paper copy] a process for its preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said active compound in therapy. The compound is an inhibitor of the enzyme MPO... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090124641 - Mitotic kinesin inhibitors: The present invention relates to fluorinated 2-aminomethylquinazolinone derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090124643 - Use of a cannabinoid cb1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy: The present invention relates to the use of cannabinoid CB1 receptor antagonist for the preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090124642 - Crystalline forms of erlotinib hci and formulations thereof: The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof.... Agent: Merchant & Gould PC

20090124644 - Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives: e

20090124645 - Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels: This invention relates to novel pyrimidine-2,4-diamine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20090124647 - Indole derivatives as antitumoral compounds: Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R1, R2, R3, R4, R5, R6, R7, n and the dotted line take permitted meanings can be obtained from a tunicate of the family Polyclinidae, genus Aplidium, species cyaneum, and the invention further provides... Agent: King & Spalding

20090124646 - Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase: t

20090124649 - Aza spiro alkane derivatives as inhibitors of metalloproteases:

20090124648 - Synthesis and crystalline forms of npy5 antagonist: The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide and novel salts, hydrates and polymorphs thereof.... Agent: Merck And Co., Inc

20090124650 - Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instructions on effects of alcohol: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician of the effect of alcohol on the maximum concentration of oxymorphone.... Agent: Mayer Brown LLP

20090124651 - Catecholamine derivatives and prodrugs thereof: The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.... Agent: Darby & Darby P.C.

20090124652 - Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethane-sulfonate: The invention provides various crystalline forms of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate, pharmaceutical compositions, methods of making, and methods of use.... Agent: Foley And Lardner LLP Suite 500

20090124653 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090124654 - Aryl and heteroaryl compounds, compositions, methods of use: This invention provides aryl and heteroaryl compounds of formula (X). The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. Formula (X) wherein R102 is selected from the... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20090124655 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090124656 - Heterocyclic oxime compounds a process for their preparation and pharmaceutical compositions containing them: e

20090124657 - Pharmaceutical compositions comprising montelukast: Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof.... Agent: Dr. Reddy''s Laboratories, Inc.

20090124658 - Treatments for viral infections: The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenyloin, in combination with multivitamins as an anti-viral composition and methods... Agent: Frommer Lawrence & Haug

20090124659 - Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors: The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.... Agent: The Firm Of Hueschen And Sage

20090124660 - Piperidine compounds useful as malonyl-coa decarboxylase inhibitors: The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and... Agent: Fish & Richardson P.C.

20090124661 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck And Co., Inc

20090124662 - Migrastatin analogs in the treatment of cancer: In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present... Agent: Choate, Hall & Stewart LLP

20090124663 - Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20090124664 - (r)-arylalkylamino derivatives and pharmaceutical compositions containing them: The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined in the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds... Agent: Clark & Elbing LLP

20090124665 - Potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20090124666 - Trpv1 antagonists: e

20090124667 - Novel dual-use peptidase inhibitors as prodrugs for a therapy of inflammatory and other diseases:

20090124668 - Cyclic derivatives as modulators of chemokine receptor activity:

20090124669 - Structural analogues of avenanthramides, their use in compositions useful in the treatment of dermatological disorders: Novel compounds for the prevention and treatment of dermatological disorders with an immunoallergic, hyperproliferative and inflammatory component, and a method of producing such compounds. The compounds are bioisosteres of substances with avenanthramide structures.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090124670 - Method for designing formulation of self-emulsifying preparation: The present invention provides a High Throughput Formulation Screening system for quickly preparing and evaluating, at low cost, a Self-Emulsifying Drug Delivery System formulation containing ingredients in a viscous liquid state or in a semi-solid or solid state. More specifically, the present invention provides a method for formulation designing of... Agent: Darby & Darby P.C.

20090124671 - Trpv1 antagonists: e

20090124672 - Aldh-2 inhibitors in the treatment of psychiatric disorders:

20090124673 - Method for treating diabetic nephropathy: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090124674 - Method for treating congestive heart failure: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090124675 - Inhibitors of anti-apoptotic proteins: wherein each of R1, and R2 comprises hydrogen, a substituted or unsubstituted straight-chained aliphatic group, a halogen, an alkoxyl, a halogen-substituted alkyl, a halogen-substituted alkoxyl, hydroxyl, carboxyl, cyano group, an amido group, a substituted or unsubstituted cycloaliphatic group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heterocyclic... Agent: Dla Piper LLP (us)

20090124676 - Substituted cyclopentanes having prostaglandin activity: e

20090124677 - Method for obtaining a pharmaceutically active compound (irbesartan) and its synthesis intermediate: It is provided a method for obtaining Irbesartan polymorph A, with few synthesis steps, by coupling the intermediate of formula (II) with the compound of formula (III), neutralising one of its alkaline salts in an aqueous medium and recrystallising the crude product obtained. The utilisation of said method obviates protection... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20090124678 - Combined use of metconazole and epoxiconazole for reducing or preventing the contamination of cereals with mycotoxins: The invention relates to the combined use of metconazole and epoxiconazole for reducing or preventing the contamination of cereals with mycotoxins formed by mould fungus producing trichothecene.... Agent: Birch Stewart Kolasch & Birch

20090124679 - Agricultural or horticultural bactericide composition and method of controlling plant disease: wherein R1 and R2 each independently represents C1-4 alkyl, etc.; Y represents H, halogen, etc.; R3 and R4 each independently represents a hydrogen atom, alkyl, etc.; R5, R6, R7 and R8 each independently represents a hydrogen atom, alkyl, etc., and (b) at least other fungicide selected from the group consisting... Agent: Sughrue-265550

20090124681 - Beta-lactone compounds: e

20090124680 - Use of prodrug composition containing naphthoquinone-based compound for manufacture of medicament for treatment or prevention of diseases involving metabolic syndrome:

20090124682 - Indan-amide derivatives with glycogen phosphorylase inhibitory activity: A compound of the formula (1) or a pharmaceutically-acceptable salt: (A chemical formula should be inserted here—please see paper copy enclosed herewith) (1) possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds... Agent: Morgan Lewis & Bockius LLP

20090124683 - Mercaptan and seleno-mercaptan compounds and methods of using them: Novel mercaptan compounds, particularly those including a photolabile protecting group, are described as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.... Agent: Townsend And Townsend And Crew, LLP

20090124684 - Stimulation of cpt-1 as a means to reduce weight: This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for... Agent: Hunton & Williams LLP Intellectual Property Department

20090124685 - Agave syrup extract having anticancer activity: The present invention comprises an agave syrup stored for at least eight weeks, having phytochemicals preferably selected from the group comprising flavonoids, polycosanols and sapogenins, which provide anticancerigen and antioxidant properties to the agave syrup. It is also described an extract of said agave syrup and a related method for... Agent: Young & Thompson

20090124686 - Gsk-3 inhibitors: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3β, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's... Agent: Intellectual Property / Technology Law

20090124687 - Benzofuran compound and pharmaceutical composition containing the same: The present invention relates to a compound having a leukotriene (particularly leukotriene B4) inhibitory action, and useful for the prophylaxis or treatment of diseases such as allergy, asthma, inflammation, cancer and the like.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090124688 - Prostaglandin reductase inhibitors: A method of inhibiting 15-keto prostaglandin-Δ13-reductase 2 by contacting 15-keto prostaglandin-Δ13-reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also disclosed are methods of treating peroxisome proliferators-activated receptor related diseases and lowering blood glucose levels by administering to a subject in need thereof an... Agent: Occhiuti Rohlicek & Tsao, LLP

20090124689 - Cetp inhibitors: Compounds having a biphenyl group substituted with a phenyl or heteroaromatic group, as shown in Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:... Agent: Merck And Co., Inc

20090124690 - Generation of combinatorial synthetic libraries and screening for novel proadhesins and nonadhesins: The present invention relates to, in part, novel sulfate and bisphenol compounds useful for the recognition, attachment and growth of unwanted biologics on natural and manmade surfaces. Another aspect of the invention relates to combinatorial libraries for producing the same. Another aspect of the invention relates to pharmaceutical formulations comprising... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090124691 - Inhibitor of increase in postprandial blood insulin level: The present invention provides an agent for inhibiting a postprandial increase in blood insulin level, wherein the agent containing a monoacylglycerol as an active ingredient. An agent of the invention for inhibiting a postprandial increase in blood insulin level contains a monoacylglycerol as an active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090124692 - Methods and pharmaceutical compositions for decorporation of radioactive compounds: A composition for removing a radioactive element or compound such as systemic transuranic compounds, from mammals comprises a pharmaceutical carrier and a decorporation agent comprising ester and amide derivatives of DTPA. A method of treating a mammal to remove systemic compounds utilizing the DTPA derivatives is also disclosed.... Agent: King & Schickli, PLLC

20090124693 - Cosmetic compositions comprising hydroxyfatty acids: The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and... Agent: Nixon & Vanderhye, PC

20090124694 - Method of producing retinyl esters: A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester.... Agent: Unilever Patent Group

20090124695 - Prostaglandin e1 and e2 analogs for the treatment of various medical conditions: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction,... Agent: Reising, Ethington, Barnes, Kisselle, P.C.

20090124696 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090124697 - Inhalation formulations of treprostinil: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions.... Agent: Foley And Lardner LLP Suite 500

20090124698 - Selective estrogen receptor modulator compositions and methods for treatment of disease: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.... Agent: Woodcock Washburn LLP

20090124699 - Silicone material for releasing an active molecule: The invention concerns a material, preferably adhesive, for releasing an active molecule for cosmetic use or personal care or a pharmaceutically or biologically active molecule for pharmaceutical use, which is formed of a silicone substance, preferably adhesive, wherein is incorporated said molecule and a compatibility agent wherein said active molecule... Agent: Buchanan, Ingersoll & Rooney PC

20090124700 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090124701 - Use of alkamides for masking an unpleasant flavor: An individual alkamide and/or a mixture having two or more different alkamides, is disclosed for changing, masking or reducing the unpleasant flavor impression of an unpleasant-tasting substance or mixture of substances. The alkamide can be trans-pellitorine; cis-pellitorine; 2Z,4Z- or 2Z,4E-decadienoic acid-N-isobutylamide; 2E,4E-decadienoic acid-N-([2S]-2-methylbutyl)amide; 2E,4E-decadienoic acid-N-([2R]-2-methylbutylamide); 2E,4Z-decadienoic acid-N-(2-methylbutyl)amide; achilleamide; sarmentine; 2E-... Agent: Connolly Bove Lodge & Hutz LLP

20090124702 - Pharmaceutical compositions of metformin: The present invention relates to an extended release dosage form of highly water-soluble antidiabetic drug metformin or its pharmaceutically acceptable salts. This invention also relates to methods for preparing the extended release dosage forms of metformin or its pharmaceutically acceptable salts.... Agent: Jay R Akhave

20090124703 - Xanthohumol-enriched hop extract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for... Agent: Jeffrey D. Hsi Edwards Angell Palmer & Dodge LLP

20090124704 - Therapeutic foam: A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090124705 - Carbon nanotube powder, carbon nanotubes, and processes for their production: A novel carbon nanotube powder containing carbon nanotubes which have a roll-like structure, also novel carbon nanotubes having a roll-like structure, novel processes for the production of the carbon nanotube powders and of the carbon nanotubes, and their use as an additive or substrate for various applications are described.... Agent: Norris, Mclaughlin & Marcus, P.A.

20090124706 - Contact lens solution and method for hydrophilizing contact lens by using the same: It is an object of the present invention to provide a contact lens solution that imparts stable hydrophilicity even to a surface of a contact lens having strong water repellency. There was prepared a contact lens solution comprising a copolymer of N-p-vinylbenzyl-D-lactonamide and at least one monomer copolymerizable therewith. The... Agent: Burr & Brown

20090124707 - Nonspecific adsorption inhibitor of substance relating to living body and method for coating article: a nonspecific adsorption inhibitor of a substance relating to a living body, which inhibits nonspecific adsorption of a substance relating to a living body such as various species of proteins which are used in clinical diagnostic agents, clinical diagnosis devices, biochips and the like, and a method for coating an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090124708 - Collagenous tissue compositions: Implant compositions are disclosed consisting of a biocompatible carrier medium such as a saline or dextran solution and particles of collagenous material dispersed therein. The collagenous material is derived from tissue which has been milled to provide fragments of collagen fibres which preserve the architecture of the original fibres and... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090124709 - Analytical methods for validating excipient purity: The invention concerns methods of validating the purity of n-Dodecyl beta-D-maltoside (DDM), a membrane permeation enhancer used in nasal and oral drug delivery methods, using HPLC and Mass Spectrometry techniques.... Agent: Goodwin Procter LLP Attn: Patent Administrator

  
05/07/2009 > patent applications in patent subcategories. archived by USPTO category

20090118158 - Compositions for enhanced epithelial permeation of peptide yy for treating obesity: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount... Agent: Woodcock Washburn LLP

20090118159 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes: a

20090118160 - Heterocyclic compounds and methods of use: provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases,... Agent: Novartis Corporate Intellectual Property

20090118166 - Conditioned decellularized native tissues for tissue restoration: The invention provides a composition conditioned for the remodeling, restoration, repair, or replacement of tissue within a host. The composition is conditioned by culturing cells on the matrix and/or by exposing the cultured cells or matrix to one or more stressors.... Agent: K&l Gates LLP

20090118163 - Factor h for the treatment of chronic nephropathies and production thereof: The invention is directed to novel uses of Factor H, in particular in antibody-independent chronic nephropathies, e.g. in tubulointerstitial fibrosis (TIF). The invention is further directed to novel large scale manufacturing processes for Factor H.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090118162 - Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival: Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection,... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090118165 - Method of treating chemotherapy-induced thrombocytopenia: A method of treating chemotherapy-induced thrombocytopenia includes administering to a subject undergoing chemotherapy a therapeutically effective amount of a Bax-inhibiting peptide.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090118164 - Methods and compounds for the targeted delivery of agents to bone for interaction therewith: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.... Agent: Stites & Harbison PLLC

20090118161 - Treatment of medical condition with a2 domain of von willebrand factor: The present invention is directed to methods for the prevention, treatment and/or diagnosis of a medical condition, such as sepsis, systemic inflammatory reaction syndrome, and/or thrombosis, for example. In particular, the method employs part or all of the A2 domain of von Willebrand factor. In certain cases, a recombinant A2... Agent: Fulbright & Jaworski, LLP

20090118167 - Selective vpac2 receptor peptide agonists: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.... Agent: Eli Lilly & Company

20090118168 - Topical adminstration of acyclovir: The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a acyclovir compound. Methods of treatment, and methods of preparing the topical composition are also provided.... Agent: Emisphere Technologies, Inc

20090118170 - Buccal, polar and non-polar spray or capsule: Buccal aerosol sprays or capsule using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprises formulation I: polar solvent 37-98.58%, active compound 0.005-55%, optionally containing... Agent: Dickstein Shapiro LLP

20090118169 - Novel compounds and pharmaceutical use thereof: c

20090118188 - Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.... Agent: Ropes & Gray LLP

20090118191 - Anti-antiogenic fragments of pigment epithelium-derived factor (pedf): The present invention provides anti-angiogenic derived from pigment epithelium-derived factor (PEDF) pharmaceutical compositions comprising the peptides, and methods of preventing angiogenesis. Such methods are useful in treating angiogenesis-associated disorders and diseases.... Agent: Marshall, Gerstein & Borun LLP

20090118175 - Compositions and methods for detection, prognosis and treatment of breast cancer: The present invention relates to methods of detection, prognosis and treatment of breast cancer using a plurality genes or gene products present in normal and neoplastic cells, tissues and bodily fluids. Gene products relate to compositions comprising the nucleic acids, polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives, agonists and... Agent: Licata & Tyrrell P.C.

20090118181 - Compositions and methods for producing bioactive fusion proteins: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of... Agent: Amgen Inc.

20090118183 - Erythropoietin receptor peptide formulations and uses: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages... Agent: Darby & Darby P.C.

20090118182 - Fibroblast growth factor-like polypeptides: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090118192 - Methods useful in the treatment of bone resorption diseases: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a... Agent: Stoel Rives LLP - Slc

20090118190 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins.... Agent: Eli Lilly & Company

20090118189 - Novel angiogenic composition-based methods: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.... Agent: Kent H. Cheng, Esq. Cohen, Pontani, Lieberman & Pavane

20090118174 - Novel peptides and methods for the treatment of inflammatory disorders: Novel peptides, nucleic acids encoding them, and derivatives of the peptides are described. The peptides and nucleic acids are of use in modulating β2 integrin function and in treating β2 integrin-mediated inflammatory disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090118184 - Recombinant factor viii having increased stability: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates... Agent: Nixon Peabody LLP - Patent Group

20090118185 - Recombinant factor viii having reduced inactivation by activated protein c: The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors,... Agent: Nixon Peabody LLP - Patent Group

20090118187 - Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto: The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue.... Agent: Ropes & Gray LLP

20090118172 - Shortened glucagon-like peptide 1(sglp-1) preparation method and application: His-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu (SEQ ID NO: 2). In comparison with the present GLP-1 and its similar compound, the shortened glucagon-like peptide 1(sGLP-1) in this invention has the following prominent advantages: 1. After reconstruction, the shortened peptide chain has stronger simulation to islet cell captors and stronger insulin secretion stimulation action; 2. the... Agent: Squire, Sanders & Dempsey L.L.P.

20090118176 - Stem cell factor-like protein scfa1 and uses thereof: Methods for stimulating epithelial cell proliferation and for treating oral and gastrointestinal disorders are described. The methods use compositions comprising stem cell factor-like protein A1 (SCFA1) polypeptides and polynucleotides.... Agent: Robins & Pasternak

20090118179 - Therapeutic agent for dentin-pulp complex regeneration: The present invention provides a therapeutic agent for regenerating a dentin-pulp complex, containing a basic fibroblast growth factor and/or a homolog thereof as an active ingredient. The present invention also provides a pulp-capping agent containing a basic fibroblast growth factor and/or a homolog thereof as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090118173 - Treatment and prevention of inflammatory bowel diseases: The present invention relates to the use of heat shock proteins, or fragments thereof, for the treatment and/or prevention of Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used.... Agent: Foley And Lardner LLP Suite 500

20090118171 - Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune: The invention relates to the use of enzymatic inhibitors of h-PRUNE and to screening method for the prevention and treatment of the metastases of tumours overexpressing h-PRUNE thereof and to the diagnostic kit for the prognosis of said metastases thereof.... Agent: Arent Fox LLP

20090118180 - Use of fusion proteins for the prevention or the treatment of pathologies resulting from ischemia: The present invention relates to the use of a fusion protein including a peptide sequence having membrane transducing properties, and a peptide sequence having cell survival properties, or a nucleic acid coding for the fusion protein, for the manufacture of a medicament intended for the prevention or the treatment of... Agent: Young & Thompson

20090118177 - Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease: Nerve growth factor (NGF), in the form of a preparation for administration on the ocular surface, is proposed for use in the therapy and/or prophylaxis of pathologies affecting brain tissues and encephalic structures, with particular reference to pathologies affecting the hippocampus, cerebral cortex, basal forebrain, medial septum, Broca's diagonal band,... Agent: Arent Fox LLP

20090118186 - Use of trail polypeptides to treat cancer: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.... Agent: Marshall, Gerstein & Borun LLP

20090118178 - Y4 selective receptor agonists for therapeutic interventions: Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36, [Glu10,Nle17,Nle30]PP2-36, their PP1-36 equivalents, and analogues and derivatives thereof as described in the specification, are selective agonists of the Y4 receptor relative to the Y1 and Y2 receptors, and are useful in the... Agent: Banner & Witcoff, Ltd.

20090118193 - Pegylated mutated clostridium botulinum toxin:

20090118194 - Measurement of melanocortin peptides and uses thereof: The present invention relates to melanocortin peptides and to methods that utilise melanocortin peptides, their measurement, their receptors and biological response systems for the risk assessment and diagnosis of disease. The biological response systems are also utilised to screen for compounds that act as agonists or antagonists of melanocortin receptors.... Agent: Ropes & Gray LLP

20090118195 - Molecules which promote hematopoiesis: The invention relates to supravalent peptide compounds depicting an enhanced efficacy. Supravalent compounds comprise several at least bivalent peptide units that bind to a receptor target and are connected to a large polymeric carrier unit.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090118196 - Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized: A composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090118197 - Immune-modulating peptide: Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or... Agent: Baker Botts L.L.P.

20090118198 - Novel peptide derivatives useful as antimicrobial agents for treating wounds: The invention relates to a compound having the general formula (I) R1—NH—CH[(CH2)n—NH—C(NH)—NH2]-CO—R2-A-R4; a pharmaceutical composition comprising said compound and use of said compound for the manufacturing of a medicament for the treatment of a disease such as a microbial disease and/or proliferation/stimulation of eukaryotic cells.... Agent: Merchant & Gould PC

20090118200 - Proline bis-amide orexin receptor antagonists: The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20090118199 - Substituted acrylamide derivative and pharmaceutical composition comprising the same: R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α;... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090118201 - Benzylbenzene derivatives and methods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.... Agent: Townsend And Townsend And Crew, LLP

20090118202 - Compositions and methods of treating hypertension with tannin complexes: The present invention includes methods and compositions to ameliorate one or more symptom of hypertension through the inhibitor of an AT1 receptor by transcriptional down regulation of an angiotensin II type 1 receptor. The composition includes an effective amount of one or more tannic acids disposed in a pharmaceutically acceptable... Agent: Chalker Flores, LLP

20090118203 - Administration of agents inducing dopachrome tautomerase (trp-2) expression for protecting hair follicle melanocytes: Agents inducing the expression of DOPAchrome tautomerase are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or... Agent: Buchanan, Ingersoll & Rooney PC

20090118204 - Methods and compositions related to esculentoside a: Disclosed are compositions related to water soluble selective COX-2 inhibitors and methods of using the inhibitors (including Esculentoside A and derivatives thereof).... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090118216 - Anaplastic lymphoma kinase (alk) as oncoantigen for lymphoma vaccination: Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein, of any species, for the preparation of a medicament, preferably a vaccine, for the treatment and/or prevention of a tumor in a subject, preferably... Agent: Nixon & Vanderhye, PC

20090118218 - Biocompatible hydrogels: A biocompatible macromer composition is provided which includes a first polymer possessing a first nucleoside, and a second polymer possessing a second nucleoside that is complementary to the first nucleoside and capable of undergoing base pairing with the first nucleoside. The biocompatible macromer composition can be used as an adhesive... Agent: Tyco Healthcare Group Lp

20090118215 - Bioresorbable controlled-release composition: A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of... Agent: Buchanan, Ingersoll & Rooney PC

20090118208 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Ropes & Gray LLP

20090118211 - Compositions and methods for enhancement of sexual function: Novel compositions and methods which utilize an erection-enhancing agent and an ejaculation-delaying agent, such that these agents provide an overlapping and/or synergistic effect, are provided. These composition and methods can be beneficially utilized for treating sexual dysfunction and/or for enhancing sexual function.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090118214 - Compositions for conferring tolerance to viral disease in social insects, and the use thereof: Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090118210 - Epididymal lipocalin gene and uses thereof: Isolated nucleic acids comprising a lipocalin gene promoter region, isolated nucleic acids comprising a human lipocalin gene, isolated nucleic acids encoding a lipocalin polypeptide, isolated lipocalin polypeptides, and uses thereof. The disclosed lipocalin nucleic acids and polypeptides can be used to generate a mouse model of male infertility, for drug... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090118219 - Flea gaba receptor subunit nucleic acid molecules: The present invention relates to flea GABA receptor subunit nucleic acid molecules; to flea GABA receptor subunit proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins,... Agent: Sheridan Ross P.C.

20090118217 - Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods... Agent: Celera Corporation

20090118212 - Methods for producing and using in vivo pseudotyped retroviruses: The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.... Agent: Viksnins Harris & Padys Pllp

20090118213 - Rna antagonist compounds for the inhibition of apo-b100 expression: Oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with either overexpression of Apo-B100,... Agent: Fish & Richardson PC

20090118206 - Rna interference for the treatment of gain-of-function disorders: The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090118207 - Use of apoptosis-specific eif-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090118209 - Use of the slug gene as a genetic marker in functions mediated by scf (stem cell factor) and applications: The Slug gene mediates the functions of SCF linking and its c-kit receptor which means that the Slug gene, the Slug gene's cDNA, Slug protein and/or drugs or substances that activate the expression of the Slug gene can be used as therapeutic agents in the mobilization of hematopoyetic stem cells... Agent: Collard & Roe, P.C.

20090118220 - Substituted adenines and the uses thereof: e

20090118221 - Method of treating arrhythmias: Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.... Agent: James J. Wong Cv Therapeutics, Inc.

20090118223 - Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives: Novel 2′-C-methyl nucleoside 5′-monophosphate and 4′-C-methyl nucleoside 5′-monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described.... Agent: Merck And Co., Inc

20090118222 - Novel pyrimidine nucleoside compound or its salt: v

20090118224 - Agent against psychosocial stresses: The invention provides an anti-psychosocial stress agent containing, as an active ingredient, uridylic acid, uridine, or uracil. Since uridylic acid, uridine, or uracil, which is an active ingredient of the anti-psychosocial stress agent of the present invention, is inexpensively available and is a biological component, the agent exhibits high safety... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090118225 - 1-methyl nicotinamide and derivatives for treatment of gastric injury: The present invention is directed to nicotinamide derivatives, and their use in treating gastrointestinal disorders.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090118226 - Intestinal eosinophil-suppressing composition: To promote the growth of human beings or animals, prevent the onset of diarrhea and prevent or ameliorate various diseases, it is intended to provide a substance which has an effect of decreasing eosinophils in the intestinal tract and a feed comprising the same as a feed additive. Namely, an... Agent: John Alexander Galbreath

20090118227 - Carotenoid-containing compositions and methods: The present invention is directed to carotenoid compositions and methods for inhibiting the growth of pathogenic bacteria or for preventing or treating bacterial infections in subjects by administration of an effective amount of astaxanthin and beta-carotene.... Agent: Bristol-myers Squibb Company - Mead Johnson

20090118228 - Carotenoid-containing compositions and methods: The present invention is directed to methods for improving optical or skin health in a subject comprising administering to the subject a combination of lutein, zeaxanthin, lycopene, and beta-carotene.... Agent: Bristol-myers Squibb Company - Mead Johnson

20090118229 - Carotenoid-containing compositions and methods: The present invention is directed to carotenoid-containing compositions and methods for improving bone or respiratory health in a subject comprising administering to the subject a combination of lycopene, beta-carotene, and beta-cryptoxanthin.... Agent: Bristol-myers Squibb Company - Mead Johnson

20090118230 - Fucose containing proteoglycan or acidic glycan and their pharmaceutical use: A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and γδT cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and... Agent: Gradimir Misevic

20090118231 - Pectin-modified resistant starch, a composition containing the same and method for preparing resistant starch: This invention relates to a pectin-modified resistant starch prepared by cross-linking starch with pectin by pectinesterase reaction. Such resistant starch is low amylase digestible and thus is useful in food products, including nutritional supplements, to reduce calorie content and increase fiber content. This invention also relates to a composition containing... Agent: Ladas & Parry LLP

20090118232 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act... Agent: Millen, White, Zelano & Branigan, PC

20090118233 - Heterocyclic compounds having inhibitory activity against hiv integrase: e

20090118234 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090118235 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090118236 - Novel phosphorus-containing thyromimetics: The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090118237 - Carisoprodol, phenytoin and fosphenytoin articles and methods: A method of using carisoprodol, phenytoin or fosphenytoin comprises informing a user that co-administration of carisoprodol with phenytoin or fosphenytoin results in an increase in free phenytoin blood levels, a decrease in total phenytoin levels, or both. In another embodiment, a method of using carisoprodol, phenytoin or fosphenytoin comprises informing... Agent: Cantor Colburn, LLP

20090118205 - Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer: The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090118238 - Deuterium-enriched alendronate: The present application describes deuterium-enriched alendronate sodium, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090118239 - Amorphous and crystalline forms of ibandronate disodium: Provided are amorphous and crystalline forms of ibandronate disodium, as well as processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20090118240 - Local treatment of neurofibromas: A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090118241 - Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20090118242 - Injectable capsaicin with non-steroidal anti-inflammatory adjunctive agent: Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering an effective amount of a NSAID to decrease an undesired effect of the capsaicinoid.... Agent: Davidson, Davidson & Kappel, LLC

20090118243 - Compositions and methods for the treatment of ophthalmic conditions: The invention relates to methods of treating ophthalmic conditions comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound.... Agent: Ropes & Gray LLP

20090118244 - Benzodiazepinone compounds useful in the treatment of skin conditions: The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.... Agent: Casimir Jones, S.c.

20090118245 - Medicament: The present invention relates to a medicament which contains as the active ingredient combination at least one gestagen with a contraceptive action as the sole hormone component and at least one insulin sensitiser, which medicament is in particular suitable for preventing or treating pathological disorders which are caused by polycystic... Agent: Norris, Mclaughlin & Marcus, Pa

20090118247 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090118246 - Therapeutic ophthalmic compositions containing retinal friendly recpients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090118248 - 3-alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof: wherein R1 is an alkoxy group and R2 is an optionally substituted, N-attached heteroaryl. The hydrogen at the 5-position can be α or β isomer, preferably α. Preferably the compound of Formula I is 17β isomer. The invention also relates to novel 3α-hydroxy-3β-substituted-17-substituted steroid compounds having GABAA receptor modulating activity,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090118249 - Dheas inhalation compositions: The present invention provides compositions for aqueous suspension comprising DHEAS and a divalent cation. The suspension in combination with a nebulizer or nasal pump spray can be administers as an aerosol for the treatment of respiratory diseases and conditions. The present invention also provides methods for making compositions in form... Agent: Wilson Sonsini Goodrich & Rosati

20090118250 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090118251 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090118252 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090118253 - Compositions and methods for treating dysfunctional uterine bleeding: The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating dysfunctional uterine bleeding. The instant invention is also relevant to the treatment and/or prevention of anemia in patients with dysfunctional uterine bleeding.... Agent: Howrey LLP - East

20090118254 - Histamine h3 receptor agents, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20090118255 - Crp lowering agent: The present invention provides a novel drug which is useful as a preventive and/or therapeutic agent for various diseases involved in elevation of CRP level, in particular, inflammatory disease and cancer comprising a compound having inhibitory activity against squalene synthase or a salt thereof, or a prodrug thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20090118256 - Chronotherapeutic diltiazem formulations and the administration thereof: A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090118257 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating... Agent: Morrison & Foerster LLP

20090118258 - Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists: The present invention relates to certain pharmaceutical compositions containing at least one vasopressin receptor antagonist and at least one angiotensin converting enzyme (ACE) inhibitor and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of vasopressin and/or angiotensin converting enzyme mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090118259 - Pharmaceutical use of substituted amides: The use of substituted amides for modulating the activity of 11-hydroxysteroid dehydrogenase type 1 (11HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture... Agent: Transtech Pharma, Inc.

20090118260 - Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin: e

20090118261 - Quinazolinone derivatives and their use as b-raf inhibitors: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20090118262 - Non-aqueous water-miscible materials as vehicles for drug delivery: A pharmaceutical composition includes at least one pharmaceutical component having a low aqueous solubility and at least one non-aqueous water-miscible material. Such a pharmaceutical composition is useful in providing a therapeutically meaningful amount of such pharmaceutical component at a target tissue. The pharmaceutical composition is particularly suitable for administration to... Agent: Bausch & Lomb Incorporated

20090118264 - Medicament having neovascularization promoting action: Methods of use of medicaments having neovascularization promoting action, which medicaments comprise a retinoid antagonist such as 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1-,4]diazepin-13-yl)benzoic acid as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20090118263 - Novel adenine compound: An adenine compound represented by the formula (1): (1) [wherein A1 and A2 each independently represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L1, L2, and L3 each independently represents alkylene or a single bond, provided that any methylene or methine group in L2 or L3 may be bonded... Agent: Birch Stewart Kolasch & Birch

20090118265 - Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as... Agent: Birch Stewart Kolasch & Birch

20090118266 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20090118267 - Indanes: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20090118268 - Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.C.

20090118269 - Methods for treating spinal muscular atrophy using tetracycline compounds: Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090118270 - Phosphodiesterase 4 inhibitors: t

20090118271 - Phosphodiesterase 4 inhibitors:

20090118272 - Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors:

20090118277 - 3 unsubstituted n-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as kinase inhibitors: The invention relates to 3-unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidine compounds, their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful... Agent: Novartis Corporate Intellectual Property

20090118278 - Compositions useful as inhibitors of gsk-3: e

20090118273 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK,... Agent: Novartis Corporate Intellectual Property

20090118274 - Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s: Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.... Agent: Woodcock Washburn LLP

20090118275 - Thiazolopyrimidine p13k inhibitor compounds and methods of use: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro,... Agent: Viksnins Harris & Padys Pllp

20090118276 - Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors: m

20090118279 - Compound containing basic group and use thereof: The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human... Agent: Sughrue-265550

20090118280 - Compounds which potentiate ampa receptor and uses thereof in medicine: e

20090118281 - Amino alcohol derivatives and their use as renin inhibitor: The application relates to novel amino alcohols of the general formula (I) where R, R1, R2, R3, R4, R5 and R6 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090118282 - Compounds and methods for treatment of amyloid-beta-peptide related disorders: The present invention relates to compounds, preparation and uses thereof, particularly in the pharmaceutical industry. The present invention discloses novel compounds more particularly useful for the treatment of Alzheimer's disease and other similar diseases, and more specifically the inventive compounds modulate (in particular, inhibit) the level of amyloid-β peptide (Aβ)... Agent: Nixon & Vanderhye, PC

20090118283 - Amide derivatives as kinase inhibitors: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar1, Ar2, R1, R3, p and n have the meaning defined in the claims In particular, the... Agent: Wolf Greenfield & Sacks, P.C.

20090118284 - Novel compounds that are erk inhibitors: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090118285 - Use of kcnq-openers for treating or reducing the symptoms of schizophrenia: The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090118286 - Heterobicyclic acrylamides: e

20090118287 - Organic compounds:

20090118288 - N-benzyl-morpholine derivatives as modulators of the chemokine receptor: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.... Agent: Fish & Richardson P.C.

20090118289 - (biphenyl) carboxylic acids and derivatives thereof: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of γ-secretase... Agent: Nixon Peabody, LLP

20090118290 - Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and γ-secretase. Also provided are methods... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090118291 - Histone deacetylase inhibitors: This invention relates to hydroxamic acid derivatives having a carbamate linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and... Agent: Merck And Co., Inc

20090118294 - Compositions and methods related to heart failure: The invention provides methods for reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); reducing the total number of days a... Agent: Wilmerhale/nitromed

20090118292 - Cytokine inhibitors: Each variable is defined in the specification. This invention relates to a method of decreasing a level of a cytokine (e.g., TNFα or interlukine such as IL-1β) in a subject with a compound of Formula I. It also relates to a method of treating a disorder mediated by an overproduction... Agent: Occhiuti Rohlicek & Tsao, LLP

20090118293 - Methods for reducing hospitalizations related to heart failure: The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration... Agent: Wilmerhale/dc

20090118295 - Chemical compounds: The use of a compound of formula I wherein Y is a single bond, C═O, C═S or S(O)m, where m is 0, 1 or 2; the ring is a 6-membered aromatic or is a 5 or 6 membered heteroaromatic ring; Z and Z′ are joined by a single or a... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090118296 - Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; lipid disorders;... Agent: Merck And Co., Inc

20090118297 - Polymorphs of dasatinib and process for preparation thereof: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.... Agent: Kenyon & Kenyon LLP

20090118298 - Octahydropentalene compounds as chemokine receptor antagonists: pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases... Agent: Abbott Bioresearch

20090118299 - Agent for prevention or treatment of glaucoma: There is Provided an Agent for Prevention of glaucoma or an agent for prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. An agent for prevention or treatment of glaucoma comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090118300 - Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.... Agent: Merck And Co., Inc

20090118301 - Compositions and methods for treating cancer: The invention provides compounds useful for treating or effecting prophylaxis of cancers, particularly cervical cancer.... Agent: Townsend And Townsend And Crew, LLP

20090118302 - Novel benzopyran derivatives having inhibitory activities against liver fibrosis and cirrhosis and their pharmaceutical uses: The present invention relates to a novel benzopyran derivative having goodantagonistic activity on TGF-β receptor which can be effectively used as a prophylactic and therapeutic agent for liver disease as well as several fibroplasiadiseases such as hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, dermatosclerosis, glomerular fibrosis and the like; and a... Agent: Frommer Lawrence & Haug

20090118303 - Serotonin 5-ht3 receptor agonist: A serotonin 5-HT3 receptor agonist containing a compound represented by the general formula (1) [R1, R3 and R5 represent hydrogen atom, a lower alkyl group, a lower alkenyl group, a halogen atom, hydroxyl group, amino group, a lower alkoxy group, carboxyl group, carbamoyl group, or nitro group, R2 and R4... Agent: Greenblum & Bernstein, P.L.C

20090118304 - 2-heteroaryl-substituted indole derivative: In the formula, R1 represents an aryl or the like; R11 represents an aryl or the like; R2 represents a formyl or the like, R3 represents a C1-6 alkyl or the like; R3 represents a hydrogen atom or the like; Z1 represents —O— or the like; Z2 represents —O— or... Agent: Merck And Co., Inc

20090118305 - Pyridine and pyrazine derivatives - 083: or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the... Agent: Astrazeneca R&d Boston

20090118307 - Aryl sulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090118306 - Novel use of liver x receptor agonists: The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such... Agent: Crowell & Moring LLP Intellectual Property Group

20090118309 - Selective antagonists of a2a adenosine receptors: e

20090118308 - 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and -pyrimidines as antiviral agents: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (hypoxanthine), 2-amino-6-hydroxypurine (guanine), 2,6-diamino-purine, 2-amino-6-azidopurine, 2-amino-6-halo substituted purines such as 2-amino-6-chloropurine, 2-amino-6-fluoropurine, 2-amino-6-alkoxypurines such as 2-amino-6-methoxypurine, 2-amino-6-cyclopropylaminopurine, 2-amino-6-alkylamino or 2-amino-6-dialkylamino substituted purines, 2-amino-6-thiopurine, 2-amino-6-alkylthio substituted purines, 3-deazapurines, 7-deazapurines and... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090118310 - Activated cdc42-associated kinase (ack) as a therapeutic target for ras-induced cancer: Methods for preventing or treating Ras-induced cancer in a patient by (a) detecting v-Ha-Ras-transformed cells in a patient and (b) administering to the patient a therapeutically effective amount of a chemotherapeutic composition comprising an effective amount of an inhibitor for activated Cdc42-associated kinase (ACK) kinase.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090118311 - Dhfr enzyme inhibitors: wherein A and D are independently —CHR7— or —NR7—; E and G are independently ═CR7— or ═N—; each R6 independently represents hydrogen or —OR7; R7 is hydrogen or C1-C6 alkyl; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase... Agent: Banner & Witcoff, Ltd.

20090118312 - Macrocylic inhibitors of hepatitis c virus: e

20090118313 - Novel compounds:

20090118314 - Tumor suppressor: (1) (wherein the ring A represents oxazole or the like; R1 represents an alkyl group, a lower alkoxy group or the like; R2 and R3 represent a lower alkyl group or the like; m represents 0 or an integer of 1 to 4, and m pieces of R1 may be... Agent: Sughrue Mion, PLLC

20090118315 - Methods of treatment using sapacitabine: )

20090118316 - Methods for augmenting bone: The present invention relates to methods of stimulating osteoblast function with a PYK2 inhibitor in subjects with osteoporosis, bone fractures, non-unions, pseudoarthroses, periodontal disease or other disorders of bone metabolism. Optionally, the method further comprises administration of a second therapeutic bone agent. The present invention also relates to methods to... Agent: Pfizer Inc.

20090118317 - Statin-carboxyalkylether combinations: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.... Agent: Pfizer Inc.

20090118319 - Fused and spirocycle compounds and the use thereof: The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1, R2, Q1-Q3, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat, prevent... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090118318 - Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases: The invention provides compounds of general formula wherein R and R1 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Morgan Lewis & Bockius LLP

20090118320 - Derivatives of 5,9-methanocycloocta[b]pyridin-2-(1h)-one, their preparation and use as analgesics: A compound of Formula I, a pharmaceutically-acceptable salt or a hydrate thereof, wherein R1 is H, or C1-4 alkyl; R2 is H, halogen, or C1, alkyl; R3 is H, halogen, or C1-4 alkyl, and R4 is C1-6 alkyl, aryl; or ═CR3R4 is cyclopentylidene, cyclohexylidene, 1-methylpiperidin-4-ylidene, or inden-1-ylidene; R5 is independently... Agent: Matthias Scholl

20090118321 - 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods for making such derivatives through hydrolysis of known compounds.... Agent: Davidson, Davidson & Kappel, LLC

20090118322 - Agent for repairing corneal sensitivity containing amide compound: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090118323 - Antitumor benzoylsulfonamides: The present invention provides antitumor compounds of the formula (I); and antitumor methods.... Agent: Eli Lilly & Company

20090118324 - Mapk/erk kinase inhibitors: e

20090118325 - 5-thioxylopyranose compounds: in which the pentapyranosyl group represents a free or substituted 5-thio-β-D-xylopyranosyl group; R′, R″ and R′″ each independently represent a hydrogen atom, a C2-C6 acyl group, or two adjacent ones of them form a 1-methylethylidene bridge; X1 and X2 each represent carbon or nitrogen; Y1 and Y2 each independently represent... Agent: Crowell & Moring LLP Intellectual Property Group

20090118326 - Nicotinic acetylcholine receptor modulators: The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090118327 - Substituted 1-amino-4-phenyl-dihydroisoquinolines, methods for the production thereof, use thereof as a medicament, and medicaments containing them: e

20090118329 - Novel substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use: In which R1-R11 are more specifically defined herein. These substituted 2-amino-4-phenyl-dihydroquinolines are useful the treatment of various renal and respiratory disorders such as acute or chronic renal failure, for impairments of biliary function and respiratory impairments such as snoring, sleep apneas or stroke. Formulations comprising them and methods for their... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090118328 - Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20090118330 - Diurea derivatives: The present invention relates to novel diurea derivatives that block intracellular signal transduction and thereby inhibit the production of pro-inflammatory cytokines, especially interleukin-2 (IL-2) and/or induce apoptosis in activated T-cells. It further discloses such a compound for use as a medicament, the use of said compound for the manufacturing of... Agent: Buchanan, Ingersoll & Rooney PC

20090118331 - Use of lobeline epimers in the treatment of central nervous system diseases, pathologies, and drug abuse: Methods of delivering or administering stabilized formulations or compositions having predetermined ratios, or range of ratios, of constituent epimers to an individual or a mammal for treatment of central nervous system diseases, pathologies, and drug abuse and compositions for stabilizing the compositions. In one embodiment, the predetermined ratios of constituent... Agent: Gfd Patents, LLC

20090118332 - Therapeutic agents - 551: t

20090118333 - Amides useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090118334 - Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker: A pharmaceutical composition including a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease by identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said... Agent: Knobbe Martens Olson & Bear LLP

20090118335 - Acid secretion inhibitor: wherein ring A is a saturated or unsaturated 5- or 6-membered ring group optionally having, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, ring-constituting atoms X1 and X2 are each a carbon atom or... Agent: Edwards Angell Palmer & Dodge LLP

20090118336 - Pyrazole derivatives and their use as pi3k inhibitors: or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme... Agent: Morgan Lewis & Bockius LLP

20090118337 - Methods and compositions for treating inflammation: A method of treating a subject with a cystic fibrosis related disorder includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090118338 - Aryl amides useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090118339 - Lysine related derivatives as hiv aspartyl protease inhibitors: The present invention concerns lysine related derivatives, their use as protease inhibitors, in particular as HIV aspartyl protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present lysine related derivatives with another anti retroviral agent.... Agent: Philip S. Johnson Johnson & Johnson

20090118340 - Method for inhibiting and/or preventing formation of cancer metastases and seconddary malignant cancers: e

20090118341 - Method for treatment of chronic neuropathic pain: Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may... Agent: Oppedahl Patent Law Firm LLC

20090118342 - Design and synthesis of biotinylated probes for n-acyl-ethanolamines: The present invention relates to the synthesis and characterisation of biotinylated analogue of N-arachidonoylethanolamine (AEA) and its use as a tool to study AEA transport and trafficking through biochemical and morphological techniques. In particular biotinylated AEA (b-AEA, for which we propose the common name MM22) is suitable to design highly... Agent: Nixon & Vanderhye, PC

20090118343 - Treatment of severe distal colitis: This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided.... Agent: Wolf Greenfield & Sacks, P.C.

20090118345 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.... Agent: Vance Intellectual Property, PC

20090118344 - Crystalline chemotherapeutic: N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090118346 - Alkyl-analide producing method: [

20090118349 - Bis-alkylating agents and their use in cancer therapy:

20090118348 - Drug-introduced photo-crosslinked hyaluronic acid derived gel: A drug-introduced photo-crosslinked hyaluronic acid derived gel which is a photo-crosslinked hyaluronic acid gel into which a drug is introduced through a covalent bond, and has characteristics that are capable of extruding from an injection device. The drug-introduced photo-cross-linked hyaluronic acid derived gel is capable of extruding, for example, by... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090118347 - Method of treating down syndrome: A method of, or the use of compounds of the invention for, treating the cognitive impairments associated with Down syndrome, the method or use comprising treating or administering to a person with an effective amount of phenserine and isomers thereof or a pharmaceutically acceptable salt and derivatives thereof.... Agent: Traskbritt, P.C.

20090118350 - Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation: Pharmacogenetics was used to evaluate the effect of polymorphisms in select candidate genes on the response of patients with chronic constipation to tegaserod (Zelmac®/Zelnorm®). The analysis identified twelve single nucleotide polymorphisms (SNPs) in six genes (HTR4, HTR3B, MLN, AQP3, SLC12A2, SCNN1A) that were associated with at least a 60% response... Agent: Novartis Institutes For Biomedical Research, Inc.

20090118351 - Angiotensin i-converting enzyme (ace) inhibitors: This invention relates to a process for synthesising an amino acid derivative of a tripeptidomimetic, such as lisinopril. The invention also relates to a derivative of lisinopril, incorporating a amino acid moeity such as tryptophan at the P2′ position.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090118352 - Broad spectrum microbicidal and spermicidal compositions and methods: i

20090118353 - Medicinal composition: The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT4) and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090118355 - Fluorotaxoids: The invention relates to fluorinated second generation taxoid compounds, pharmaceutical formulations thereof, and their use for inhibiting the growth of cancer cells in a mammal.... Agent: Hoffmann & Baron, LLP

20090118354 - Liquid pharmaceutical formulations of docetaxel: There is provided a liquid pharmaceutical formulation for parenteral administration comprising: docetaxel or a pharmaceutically acceptable salt thereof; one or more glycols; and a pharmaceutically acceptable nonaqueous solvent system; wherein the formulation has a pH meter reading in the range of from 2.5 to 7.... Agent: Kenyon & Kenyon LLP

20090118356 - Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents: e

20090118357 - Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field: Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, —CnH2n-1, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090118359 - Food product: A method for the treatment of a bioflavonoid composition, comprising the contacting of the bioflavonoid composition with ethanol of at least 90% purity at a temperature of from 10 to 80° C. for a period of at least 0.5 hour, followed by separation of the ethanol and the bioflavonoid, wherein... Agent: Unilever Patent Group

20090118358 - Kainate receptor-selective epimeric analogs of dysiherbaine: Disclosed are compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a GluR5 receptor, a GluR6 receptor, or both receptors. The pharmaceutical compositions include and the methods utilize compounds that are analogs and stereoisomers of dysiherbaine and neodysiherbaine which have specificity for kainate receptors.... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090118360 - Process for manufacturing leaf tea: Disclosed is a process comprising the steps of: expressing juice from fresh tea leaves thereby to produce leaf residue and tea juice wherein the amount of expressed juice is greater than 300 ml per kg of fresh tea leaves; subjecting the fresh tea leaves and/or the leaf residue to an... Agent: Unilever Patent Group

20090118361 - Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor: A suppressor of the expression of MCP-1 is provided that is excellent in safety and is widely applicable to, for example, foods. The suppressor of the expression of MCP-1 according to the present invention is characterized by containing auraptene. Auraptene is contained in citrus fruits such as Hassaku, Amanatsu, Natsumikan,... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090118362 - Chemotherapeutic agents for inhibition of protein translation: The present invention relates to a anti-proliferative target for designing chemotherapeutic agents, which comprises a EIF4A protein having an amino acid sequence, as defined in claim 1.... Agent: Bereskin And Parr

20090118363 - Sesamin-class compound-containing foods or beverages for animals: Foods and beverages containing a sesamin-class compound(s) of 1 wt % or above and an additive acceptable as a food or beverage are provided. Methods for treating coats and/or body odors of nonhuman animals comprising administering to the nonhuman animals foods or beverages for nonhuman animals containing an effective amount... Agent: Drinker Biddle & Reath (dc)

20090118364 - Novel diterpenes from the fruiting body of antrodia camphorata and pharmaceutical compositions thereof: o

20090118365 - Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain: Methods of treating neuropathic pain, musculoskeletal pain, and back spasm associated with musculoskeletal pain in a patient comprising orally administering a therapeutically effective dose of a prodrug of a GABAB agonist having a high oral bioavailability of the corresponding GABAB agonist are disclosed.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090118366 - Organic compounds: t

20090118367 - Insecticidal compositions with disinfectant: Insecticidal compositions having insecticide and disinfectant activity are provided. Preferably, the insecticidal composition contains both an insect control agent and a disinfectant. Particularly low levels (i.e., below 20%) of at least one hydrocarbon are introduced as a solvent. The insecticidal compositions further comprise an emulsifier, buffer and antifoaming agent. These... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090118368 - Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof: The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are... Agent: Seed Intellectual Property Law Group PLLC

20090118370 - Method of treating cancer using dichloroacetate: The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg/kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and/or... Agent: Dobrusin & Thennisch PC

20090118369 - Use of cis-9, trans-11 isomer of conjugated lineoleic acid: A composition and medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases, including asthma, is provided. A method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response including administering the cis-9, trans-11 isomer of conjugated linoleic... Agent: Fox Rothschild LLP

20090118371 - Delta 6 desaturase from thraustochytrid and its uses thereof: The present invention is directed to an isolated delta-6 desaturase gene from Schizochytrium. It is further directed to the cloning of delta-6 desaturase derived from Schizochytrium in Yeast. The nucleic acid sequence and the amino acid sequences of the delta-6 desaturase are disclosed. Further disclosed are the constructs, vector comprising... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090118372 - Inhibitors of biotin protein ligase: The present invention relates to a method for identifying an inhibitor of a biotin protein ligase. The method include the steps of (a) providing a substrate, wherein the substrate may be biotinylated; (b) contacting the substrate with biotin and a biotin protein ligase in the presence of a test compound;... Agent: Birch Stewart Kolasch & Birch

20090118373 - Inhibition of cox-2 and/or 5-lox activity by fractions isolated or derived from hops: A natural formulation of compounds isolated or derived from hops which inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX) is disclosed. The hops formulations may be administered to a mammal to treat or inhibit a pathological condition associated with the activity of COX-2 and/or 5-LOX in such a mammal.... Agent: Mcdermott Will & Emery LLP

20090118374 - Sulfonamido compounds that antagonise the vanilloid trpv1 receptor: n

20090118375 - Optically active phthalamides: Novel optically active phthalamides of the formula (I) in which A, q, R1, R2, E1, E2, X, m, Y, n and Z are as defined in the description, processes for preparing these compounds and their use for controlling pests.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090118376 - Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia: This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA neuron is a dose-dependent response. This invention also discloses that NADPH oxidase plays a critical role of neuroprotection of MMT and MMT therapy for neurodegeneration... Agent: Wpat, PC Intellectual Property Attorneys

20090118377 - Apogossypolone and the uses thereof: The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell... Agent: Casimir Jones, S.c.

20090118378 - Technical information for a formula of a natural facial moisturizing cream for daytime use which contains a propylene glycol extract of plant specie solanum tuberosum: This invention relates to facial moisturizing cream used for daytime use in the cosmetics industry; it provides active antioxidants present in the extract of the plant species Solanum Tuberosum from the Peruvian Andes; which promotes the health of the skin and helps prevent the appearance of wrinkles to counteract the... Agent: Dla Piper LLP (us)

20090118379 - Process for the manufacture of a composition containing at least one xanthophyll: The present invention relates to a process for the manufacture of a composition containing at least one xantophyll selected from the group consisting of lutein and zeaxanthin, said process comprising the steps of: providing an extract of Marigold flower containing the xantophyll(s) in esterified form; saponifying the Marigold flower extract... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090118380 - Process for the preparation of water-in-oil and oil-in-water nanoemulsions: Process for the preparation of a water-in-oil or oil-in-water nanoemulsion wherein the dispersed phase is distributed in the dispersing phase in the form of droplets having a diameter ranging from 1 to 500 nm, comprising: 1) the preparation of a homogeneous water/oil blend (I) characterized by an interface tension lower... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141218: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.91289 seconds

PATENT INFO